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I. Abstract
Bone marrow mesenchymal stem cells (MSCs) may soon become the first FDA-approved
stem cell therapy for autoimmune and inflammatory disease. Our lab originally
hypothesized that much of the therapeutic activity of MSCs may be attributed to molecules
secreted by these cells. This thesis will test this hypothesis, with an emphasis on
translational steps towards clinical product development, including the identification of
novel proteins secreted by MSCs. The first part of the thesis consists of studies we
performed to test whether MSC conditioned medium (MSC-CM) can treat rats undergoing
cisplatin-induced acute kidney injury (AKI). When AKI rats were treated with MSC-CM, we
observed a survival benefit and significant protection of renal function compared to
controls. The second part of the thesis will describe the development of a device designed
for sustained delivery of MSC secreted factors to dialysis-dependent AKI subjects. We
tested these devices for cell function, stability and viability when subjected to conditions
that model future clinical operation. Finally, inspired by the therapeutic capacity of MSC
secreted factors, this thesis will conclude with the introduction of a new method that we
developed to uncover novel anti-inflammatory proteins from MSCs. This method revealed
four previously unidentified cytokine modulators, two of which we found significantly
promote IL-1 0 and suppress TNF-a in mice challenged with endotoxin. When leveraged as
novel therapeutics for lethal endotoxemic shock, these two most potent modulators
protected mice and provided for a significant survival benefit compared to vehicle controls.
Together, these results demonstrate the power of MSC secreted factors in the context of
inflammatory disease, and propose new tactics for elucidating potent secreted products
from cells.
Thesis supervisor: Martin Yarmush, MD, PhD
Title: Senior Lecturer of Surgery and Bioengineering, MGH
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1. Introduction - Mesenchymal Stem Cells as a Source of
Therapeutic Inspiration
In the past few decades, much has been learned about mesenchymal stem cells (a.k.a.
bone marrow stromal cells, mesenchymal stromal cells and multipotent stromal cells,
among other equivalents; MSCs). Clues as to their natural function, and a growing
understanding of their therapeutic potential have come as a result of the tireless efforts of
hundreds of research groups, thousands of clinicians and numerous companies across the
globe. MSCs may soon become the first FDA-approved stem cell product for inflammatory
and autoimmune diseases, and they have been shown to exhibit potent therapeutic activity
in an impressive diversity of preclinical disease models.
While much has been accomplished within the field, as a therapeutic these cells are still in
their infancy. Promising clinical data are encouraging, but there are still severe deficits in
understanding even the most basic aspects of mechanisms of action (MoA).
Pharmacokinetics / pharmacodynamics (PK/PD) analyses have thus far failed to clarify the
fate of MSCs upon transplantation in human patients. And unlike single molecule
therapeutics, MSCs behave dynamically upon transplantation, making thorough analysis as
to the MoA extremely challenging. Future efforts will need to focus heavily on these
analyses, as current methods for tracking and monitoring the fate of molecular therapeutics
are insufficient for cell-based therapies. Without a thorough and tractable analytical
scheme for optimizing MSC therapy, clinical trials are likely to sell them far short of what
they might be capable of when properly administered. Chapter 2 of this thesis will
summarize the state-of-the-art in MSC therapy, and build the proper framework for
understanding and contemplating this dilemma.
Surely, this dilemma has been a setback for the MSC transplantation community, and has
led to the proposal of alternative modes of administration of MSC therapy. A few
investigators have reported that MSC engraftment and differentiation are not necessary for
conveying therapeutic benefit, thereby eliminating the need for cell transplantation in
certain contexts. We have since surmised that lengthy optimization efforts to maximize
homing and engraftment might be unnecessary, and even suboptimal for conveying
therapeutic benefit. Early work in our lab demonstrated that contrary to popular belief at
the time, the molecules secreted by MSCs can recapitulate most, if not all of the
therapeutic activity of transplanted cells in acute inflammatory organ failure syndromes
(and likely in many other diseases of autoimmunity and inflammation as well). These first
studies revealed the surprising finding that in a rat model of fulminant hepatic failure (FHF),
whole cells administered intravenously were unable to provide any survival benefit, and yet
when the same cell mass was lysed and the molecular contents relinquished, a survival
trend was observed. Then, when the same cell mass was incubated with basal medium
and the secreted factors collected and administered intravenously, a statistically significant
survival benefit was conveyed. We subsequently developed an MSC-laden bioreactor that
was connected to the bloodstream of FHF rats for continuous delivery of MSC secreted
factors - this platform was shown to provide the best benefit of all. By pursuing this path,
our lab discovered crucial information about the MoA of MSC transplantation and
generated data to suggest that the secreted factors alone might be sufficient for therapy,
thereby significantly simplifying the problem of PK/PD characterization, and suggesting an
altemative modality for administration of MSC therapy, namely via MSC secreted factors.
In addition, our lab was able to develop a novel platform for delivery of said factors that
shows clinical promise. Subsequent work by other groups has validated our findings, and
has demonstrated the importance of MSC paracrine signaling in a variety of preclinical
disease models.
With this new understanding of the therapeutic potential of MSCs in hand, our lab has built
upon this base and explored in much greater depth how MSC secreted factors could be
leveraged to treat diseases. Soon after the initial results in FHF rats, Professor Martin
Yarmush, Dr. Biju Parekkadan, Mr. Brian Miller and I founded a company to translate the
bioreactor delivery platform for clinical use to treat patients with acute kidney injury (AKI)
and other inflammatory organ failure syndromes. We have been working together ever
since to confirm with proof-of-concept studies that the secreted factors are suitable for
AKI, and scale up of the rodent prototype device for use in humans is feasible. Chapter 3
will describe the work we have done to enable successful scale up and translation of this
system into a clinical product.
Having spearheaded primary efforts in translating this proprietary delivery system into a
clinical product for AKI, we decided in parallel to begin further analysis of the secreted
factors of MSCs with the hopes of uncovering some of the more important molecules
involved in MSC therapy. Early studies in our lab indicated that MSCs secrete hundreds of
different proteins, and likely numerous other biological molecules that could be contributing
to the therapeutic activity of the heterogeneous mixture. Indeed, other groups have also
demonstrated that there are many therapeutically relevant molecules secreted by MSCs.
Each individually could have activity, and in combination these factors are likely responsible
for the elegant and sophisticated physiological responses to MSC and MSC secreted
factors therapy. We initially viewed this as a difficult, and potentially intractable problem -
considering that MSCs secrete hundreds of proteins, arriving at an understanding of the
critical combination that is necessary for therapeutic activity could require a career of
dedicated research. In light of this challenge, we decided to instead look at the problem
from the perspective of protein therapeutics discovery - here we have a cell that has
demonstrated therapeutic activity in animals and humans, and recent evidence has
suggested that the secreted molecules are responsible for most, if not all of the therapeutic
activity. Hence, these secreted molecules, if mined correctly, could be a source of
potentially therapeutic molecules. Inspired by the natural capabilities of MSCs to reverse
many different disease with these molecules, we set out to attempt to mimic aspects of
MSC therapy by isolating individual therapeutic factors that are made by MSCs, that when
administered alone can recapitulate much of the activity of the heterogeneous mixture in
MSC-CM in certain contexts.
Once we began to look at the problem in this light, we started to see a new problem that
we would have to solve, one of methodology and utilization of state-of-the-art analytical
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techniques for mining these secreted molecules for therapeutic candidates. Many have
attempted to solve this problem in the past, using tried-and-true methods for scanning
through the secreted contents of cells looking for therapeutic candidates. Generally
speaking, the methods commonly used fall into the categories of chromatography and
mass spectrometry - for separating and identifying molecular constituents, respectively.
Naturally, we attempted to leverage these same techniques at first. However, after
purifying the secreted factors from 1x10 9 MSCs and failing to resolve single molecules, we
decided to attempt a different approach.
The approach that we developed, enriched protein screening (EPS), is described in full
detail in Chapter 4. In essence, we took a step back from analyzing the conditioned
medium directly and instead asked whether the genes expressed by MSCs could be
correlated with activity as determined by potency assessment. If so, and if we could refine
our list of correlated genes using other cells and gene expression conditions that
correspond to other levels of therapeutic activity, then perhaps we could generate a
stratification scheme to enrich our gene list. From this enriched list, we could then screen
recombinant proteins for activity in our potency assay, and then take those in vitro hits and
subject them to further analysis in mice. The result of this analysis was the identification of
four novel anti-inflammatory proteins expressed by MSCs, of which two were shown to
exhibit potent anti-inflammatory capabilities that provided a significant survival benefit to
mice challenged with the classical pro-inflammatory ligands, lipopolysaccharides. Using
this methodology, we were able to uncover multiple novel anti-inflammatory proteins that
show great promise as next-generation immunomodulatory drugs.
This thesis is intended to serve as an overview of the discoveries we have made over the
past four years that highlight the great potential of MSC therapy, with a particular focus on
the unique therapeutic capabilities of MSC secreted factors, and the development of a new
methodology for discovering new protein drugs based on MSC secretions. We are hopeful
that our proprietary delivery platform for the MSC secreted factors can make its way out of
the laboratory and into the hands of clinicians to serve the many patients suffering from
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inflammatory organ failure syndromes that are currently in desperate need of a new,
transformative therapy. In addition, we are excited that our enriched screening method has
thus far yielded several promising anti-inflammatory candidate therapeutics that might also
have clinical applications if developed properly, and are enthusiastic to apply this method
to other cell types to potentially reveal additional, potent therapeutic proteins.
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2. Mesenchymal Stem Cells as Therapeutics
2.1. Abstract
Mesenchymal stem cells (MSCs) are multipotent cells that are being clinically explored as a
new therapeutic for treating a variety of immune-mediated diseases. First heralded as a
regenerative therapy for skeletal tissue repair, MSCs have recently been shown to
modulate endogenous tissue and immune cells. Preclinical studies of the mechanism of
action suggest that the therapeutic effects afforded by MSC transplantation are short-lived
and related to dynamic, paracrine interactions between MSCs and host cells. Therefore,
representations of MSCs as drug-loaded particles may allow for pharmacokinetic models
to predict the therapeutic activity of MSC transplants as a function of drug delivery mode.
By integrating principles of MSC biology, therapy, and engineering, the field is armed to
usher in the next generation of stem cell therapeutics.
2.2. Introduction
The discovery of adult stem cells substantiated theories about the presence of regenerative
populations of cells in developed organisms and has led to growing interest in the use of
these cells as therapeutics. In particular, researchers are now exploring the use of
mesenchymal stem cells (MSCs) in preclinical and clinical studies to resolve injury by
enhancing endogenous repair programs, which represents a powerful new paradigm for
treating human disease. From systemic administration of MSCs as an intravenous
treatment to the delivery of their molecular secretions by extracorporeal devices, groups
around the globe are focusing their attentions on this cell, seeking to harness its full
therapeutic potential.
MSCs are an excellent candidate for cell therapy because (a) human MSCs are easily
accessible; (b) the isolation of MSCs is straightforward and the cells can expand to clinical
scales in a relatively short period of time [1, 2]; (c) MSCs can be biopreserved with minimal
loss of potency and stored for point-of-care delivery [3, 4]; and (d) human trials of MSCs
thus far have shown no adverse reactions to allogeneic versus autologous MSC
transplants, enabling creation of an inventory of third-party donor MSCs to widen the
number of patients treated by a single isolation [5-7]. MSC transplantation is considered
safe and has been widely tested in clinical trials of cardiovascular [8, 9], neurological [10,
11], and immunological disease [12, 13] with encouraging results. Unfortunately, within the
past year, several of the pivotal lead trials either have undergone early termination or have
failed to meet primary endpoints.
These results suggest an incomplete understanding of the underlying mechanism(s) of
action of MSC therapy and point to the importance of further preclinical development. A
more refined understanding of the natural functions of MSCs in the bone marrow may
provide the basis for insight into their primary mode(s) of action. MSCs were first
considered to be stromal progenitor cells in the bone marrow and were originally
hypothesized to serve one primary role in their undifferentiated state: replenishment of
stromal tissue in the bone marrow. However, MSCs and their stromal progeny also perform
a number of alternative functions in the bone marrow, including the secretion of soluble
mediators, which support hematopoiesis. These alternative functions are now being
characterized in the context of MSC transplantation, whereby paracrine interactions
between MSCs and host cells have been shown to relate directly to the therapeutic activity
of MSCs.
Although it has not been definitively proven whether engraftment and differentiation of
MSCs is necessary to convey this paracrine support, recent studies have suggested that
less than 1 % of systemically administered MSCs persist for longer than a week following
injection [14, 15], and the observed benefits of MSC therapy may result from the
relinquishment of their molecular contents upon administration. If this is true, engineering
approaches may improve the optimization of MSC dosing and provide for alternative uses
of MSCs to deliver drugs as active, dynamic delivery vehicles.
The aim of this review is to present an overview of the field of MSC therapy, with a
particular focus on the various hypotheses concerning the mechanism(s) of action of
MSCs. The majority of works cited focus on systemic administration of bone marrow-
derived MSCs because this therapeutic modality has been explored more extensively than
other means of administering MSC-based therapy. For alternative sources and modes of
administration of MSCs, we refer the reader to other reviews [16-18]. We begin with a brief
history of MSCs, from their initial discovery to current clinical programs using cell
transplantation. We then revisit the biological origins and natural functions of MSCs and
present the initial observations that laid the groundwork for therapeutic testing. Next, we
describe retrospective studies that support the theory that MSCs can be conceptualized as
drug-releasing particles that deliver their payloads in the course of hours to days. Finally,
we propose the development of new pharmacokinetic analysis techniques based on this
molecular-particle theory to motivate new clinical trial designs for therapeutic delivery of
MSCs. Ultimately, such engineering analyses may better predict the biological activity of
MSCs and leverage the therapeutic potential of these cells in a more rational way.
2.3. Origins and Developmental Biology of Mesenchymal Stem
Cells
In this section, we begin with historical studies that first suggested the existence of MSCs
(see Figure 2.1). We then focus on clinical studies that have used MSCs as an intravenous
therapeutic. Finally, we describe the current methods used to characterize MSC
populations and highlight the known differentiated functions of MSCs in their native, in vivo
microenvironments.
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2.3.1. History of Mesenchymal Stem Cells: From Discovery to Clinical
Therapy
The existence of a stromal precursor giving rise to mesodermal cells in the bone marrow
was originally theorized in the nineteenth century [19]. Cohnheim hypothesized a bone
marrow origin of fibroblasts implicated in distal wound healing [20]. In the early twentieth
century, Maximow described the essential relationship between newly forming blood
components and the mesoderm during embryogenesis. He initially postulated the
importance of the marrow stromal tissue in supporting the development and maintenance
of blood and hematopoietic organs [21]. These observations made by Cohnheim and
Maximow offered the first indication of a reservoir of stromal cells in the bone marrow that
were involved in the natural healing response and hematopoiesis.
In vivo transplantation of bone marrow elements in the 1960s demonstrated that stromal
precursors are directly involved in the formation of skeletal tissue cells. Friedenstein et al.
first demonstrated that stromal cells could be isolated from whole bone marrow aspirates
based on differential adhesion to tissue culture plastic-a method still widely practiced to
isolate MSCs. These stromal cells were originally described as adherent, clonogenic,
nonphagocytic, and fibroblastic in nature, with the ability to give rise to colony forming
units-fibroblastic (CFU-F) [22]. Transplantation of these marrow stromal cells under the
kidney capsule or in subcutaneous space led remarkably to the formation of ectopic
marrow. Decomposition of the origins of ectopic marrow cells revealed donor-derived bony
trabeculae, myelosupportive stroma, and adipocytes and host-derived hematopoietic cells
that colonized and matured within the space [23-25]. Experiments performed with dermal
fibroblasts or differentiated connective tissue cells failed to recapitulate the same
histological image, demonstrating that this was a phenomenon specific to the marrow
stroma. These seminal experiments illustrated an "organizing" function of MSCs similar to
other lymphoid stromal cells and suggested that MSCs were a precursor to bone marrow
connective-tissue cells.
In the late 1980s, Maureen Owen and Arnold Caplan elaborated on Friedenstein's initial
work and proposed the existence of an adult stem cell that was responsible for
mesengenesis [25, 26]. Owen et al. further characterized the marrow stroma and illustrated
the heterogeneity of the population [25, 27-30]. At the same time, Caplan and colleagues
hypothesized that a subpopulation of the marrow stroma was developmentally linked to the
mesenchymal tissues he had been studying during chick embryogenesis [26, 31]. In
addition, they identified the first set of MSC-expressed antigens that react with SH2
(CD105) and SH3 (CD73) monoclonal antibodies. Caplan and colleagues coined the term
mesenchymal stem cell to describe this subtype of marrow stromal cells involved in the
process of mesengenesis [7, 32, 33].
Shortly following the discovery of methods for isolating and culturing MSCs, the field began
to grow rapidly, and many groups began to explore their therapeutic uses. Only a few years
after MSCs were identified, human trials were commenced to evaluate safety and efficacy
of MSC therapy. Initially, autologous MSCs were explored to aid in the engraftment and
20
recovery of hematopoiesis after ablation and bone marrow transplantation for the treatment
of cancer [34, 35]. Concurrently, researchers conducted a number of groundbreaking
studies that leveraged the therapeutic potential of allogeneic MSC transplants to treat
children with osteogenesis imperfecta, a genetic disorder of skeletal dysplasia [36, 37].
Shortly thereafter, more studies were performed to investigate the utility of allogeneic
MSCs to treat patients with Hurler syndrome and metachromatic leukodystrophy [38]. The
focus of these early studies was predicated upon the fact that MSCs functioned as stromal
stem cells and therefore might be best suited to treat diseases and conditions afflicting
connective and hematopoietic tissue. These first studies were important because they
provided preliminary evidence of the safety of MSC therapy as well as the basis for good
manufacturing processes to generate MSCs on a clinical scale.
More recently, groups around the world have investigated MSC transplantation for the
treatment of myriad diseases based on a newfound appreciation for MSCs' pleiotropic
functions that enhance endogenous repair and attenuate immunological dysfunction.
Examples of clinical trial designs are provided in Table 2.1. Currently, there are 79
registered clinical trial sites for evaluating MSC therapy throughout the world
(http://clinicaftrials.gov/. The United States has the highest concentration of registered trial
sites at 28, but the rest of the world accounts for more than half of the total number (19 in
Europe, 16 in China, 5 in the Middle East, 4 in India, 3 in Canada, 2 each in Africa and
Japan, and 1 in Australia), indicating strong international interest in MSCs as a potential
therapy. The majority of trials are sponsored by academic medical centers exploring novel
applications of MSCs to treat conditions as diverse as critical-limb ischemia
(NCT00883870), spinal cord injury (NCT00816803), and liver cirrhosis (NCT00420134).
Table 2.1 - Examples of clinical trials of mesenchymal stem cell therapy reported in the academic literature
Indication Enrollment Trial Design Cell Mass Measured Study Conclusions Ref.
Parameters and
(N; N , MOA Follow-up Time
after CTx
Local advanced or
metastatic breast
cancer with high-dose
chemotherapy and
PBPC Tx given Ctx at
1 or 24 hours later
Diagnosed severe
type 111 01 with similar
growth rates
1.5-3.9x101
CD34+
cells/kg and
2.2x101
MSCs/kg
5.7-7.5 x1 08
bone
marrow
cells/kg i.v.
Neutrophil
platelet
(daily),
and (1) Prompt hematopoietic
counts engraftment of 8 days
CFU (42 days),
Mortality (100 days)
Growth analysis
(6 months)
(2) 70% CFU recovery
(3) One patient death after
100 days
Increased growth rates that
slowed over time
Patients
successful
bone
transplants
with
matched
marrow
Diagnosed ALS with
severe lower limb and
mild upper limb
impairment
(69; 35, 34) CTx 10 days after PCI
(56; 10,46) Open-label,
multicenter trial of
hematological
cancers patients
treated with CTx 4
days prior to
haploidentical BMTx
2-10 x10 8  Nerve conduction
MSCs/kg iv velocity
MentaVPhysical
Exams
MSCs
suspended
in CSF
infused into
T7-T9
exposed
spinal cord
48-60 x10 9
MSCs into
coronary
artery lesion
1, 5, or 10
x108
MSCs/kg iv
MRI (3, 6 months),
Neuromuscular
exam (3 months)
Echocardiography
(monthly)
PET (3, 6 months)
EKG (3 months)
Hematopoietic
Recovery (daily)
Acute GVHD
(1) No toxicity
(2) Improved
conduction velocity
nerve
(3) No clinical change in
overall mental or physical
status
(1) No adverse reactions
(2) No structural MRI changes
(3) Mild increase in muscle
strength of a lower limb
muscle group
(1) Decreased
dysknetic,
segments
akinetic,
hypokinetic
(2) Increased wall movement
at infract
(3) LVEF higher
(1) Prompt hematopoietic
engraftment in most patients
(2) 23/46 patients did not
undergo acute GVHD with 11
showing longer relapse time
Abbreviations: MOA, method of administration; CTx, cell transplant; MI, myocardial infarction; PCI, percutaneous coronary intervention;
MSC, mesenchymal stem cell; PET, positron emission tomography; EKG, electrocardiogram; LVEF, left ventricular ejection fraction; GvHD,
graft-versus-host disease; BMTx, bone marrow transplant; MLD, metachromatic leukodystrophy; 01, osteogenesis imperfecta; ALS,
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BMTx (23; 15,8)
(7; 2, 5)
MILD
ALS
(5; 1, 4)
(7;5, 2)
GvHD
amyotrophic lateral sclerosis; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PBPC, peripheral blood progenitor cell; CFU,
colony forming unit; Tx, transplantation; iv, intravenously.
Osiris Therapeutics, Inc., founded in 1991, has played a pivotal role in the past decade in
shaping the direction of research and development of MSC-based therapies. Concurrent
with emerging theories regarding the immunological activity of MSCs, which we discuss in
greater depth below, Osiris has developed a clinical trial program to explore the therapeutic
utility of MSCs in humans. It has pioneered studies to investigate systemic administration of
MSCs as a therapy for steroid-refractive graft-versus-host disease (GvHD), Crohn's
disease, type I diabetes mellitus (IDDM), myocardial infarction (MI), and chronic obstructive
pulmonary disease (COPD). Because early trials established a good record of safety for
direct MSC injection, many of these studies are currently in Phase II or Phase Ill trials, and
MSCs are already granted expanded access for use in pediatric steroid-refractive GvHD by
the United States Food and Drug Administration (FDA). However, in the past year, Osiris
has reported that several of its Phase 11 and Phase Ill studies were either prematurely
terminated or failed to meet primary endpoints (http://www.osiristx.com). In March 2009,
initial results for the Crohn's disease trial found a greater-than-expected placebo response,
which led the company to cease recruitment after enrolling 210 patients ih a Phase IlIl
study. In June 2009, six-month interim data of the Phase Il COPD trial were announced:
They indicated a statistically significant decrease in systemic inflammation as measured by
C-reactive protein in MSC-treated patients but no statistical improvement of lung function.
In September 2009, Osiris reported the results of two Phase Ill double-blind, placebo-
controlled trials for adult GvHD in which MSC transplants were tested either as a first-line
therapy or in patients that were refractory to standard medical treatment. Both trials
showed an insignificant improvement in mortality compared with placebo at a 28-day
endpoint (first-line therapy: N=192; 45% response rate with MSCs versus 46% response
rate with placebo; refractory therapy: N = 260; 35% with MSCs versus 30% with placebo).
Stratification of the cohorts based on subclasses of GvHD have yet to be reported but may
show benefit in specific patient populations. Nevertheless, the results of these trials may
curtail efforts to develop and validate MSC therapy in humans.
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These results may indicate an incomplete understanding of the mechanisms of action of
MSCs, and therefore an inefficient administration of the cells that does not best convey
therapeutic benefit. Many clinical trials entail the administration of MSCs systemically and
assume that MSCs engraft and provide long-term support by either directly replenishing
damaged tissue or interacting with neighboring cells to promote endogenous repair.
Currently, it is widely debated whether MSC engraftment, proliferation, and/or
differentiation are necessary for therapeutic benefit. Many new studies are now implicating
paracrine signaling as the primary mechanism of action, and a few studies have even
demonstrated that direct injection of the molecules secreted by MSCs can provide an
improved benefit above and beyond what is conveyed by transplanted whole cells [40-42].
In later sections, we discuss this issue further and present a new theory as to how MSCs
may be conveying therapeutic benefit without engraftment and differentiation-i.e., how
they instead may be acting as dynamic drug delivery vehicles.
2.3.2. Phenotype and Multipotency Analysis for the Identification of
Mesenchymal Stem Cells
One of the most elusive problems in MSC biology has been the identification of a single
marker that distinguishes a purified population of MSCs with a uniquely defined set of
functional properties. Without such an identifier, definitively comparing putative MSCs from
different tissues has been challenging. Exhaustive phenotypic analysis has therefore been
necessary to distinguish MSCs from other cells that exhibit similar fibroblastic, adherent
characteristics in culture. Table 2.2 summarizes the current phenotypic tests used to
identify MSCs.
Table 2.2 - Phenotype tests for mesenchymal stem cells and known MSC phenotypic characteristics
Phenotype Test Known MSC Phenotype Methods Used Ref.
Colony Formation
Immunophenotype
In Vitro Multipotency
Ectopic Marrow Formation
In Vivo Multipotency
Will form fibroblastic colonies after isolation
CD11-, CD14-, CD18-, CD31-, CD34-, CD40-, CD45-
, CD56-, CD80-, CD86-, MHClI-
CD29+, CD44+, CD71+, CD73+, CD90+, CD105+,
CD106+, CD120a+, CD124, CD166+, Stro-1+, ICAM-
1+, MHCl+
Will differentiate down multiple pathways:
1. Osteogenic
2. Chondrogenic
3. Adipogenic
Will form ectopic bone marrow in the presence of
bone minerals
Subset of MSCs, termed MAPCs, are capable of
contributing to all somatic cell types in mice
CFU-F assay
FACS
Induction via specialized media
Subcutaneous transplantation,
kidney capsule transplantation,
diffusion chamber transplantation
Blastocyst transplantation
"Abbreviations- CFU-F, colony forming units-fibroblastic; FACS, fluorescent activated cell sorting; MAPC, multipotent adult progenitor cell.
As described in Table 2.2, the phenotype of MSCs is defined in part by the multipotency of
these cells in culture and in vivo. Determining in vivo multipotency is a powerful tool for
assessing MSC phenotype. As far back as Friedenstein, ectopic transplantation of MSCs
has been used to determine whether the MSC-like cells are capable of inducing bone and
marrow formation [48, 50, 51]. Perhaps the most rigorous method for determining the
"stemness" of an MSC population involves the injection of MSCs into the blastocyst of a
mouse and studying the developmental progeny from the injected cell populations [49].
This method is not commonly used, however; although it was shown to be useful for a
subset of MSCs, it does not necessarily reflect the phenotype of MSCs in general.
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[22, 431
[44, 45]
[46]
[47, 48]
[49
2.3.3. Embryonic and Adult Sources of Mesenchymal Stem Cells
The developmental precursor of MSCs has been difficult to identify because MSCs have no
distinguishing features to track in vivo. A number of studies support the concept that the
typical sites of developmental hematopoiesis, including the placenta, aorta-gonad-
mesonephros, and fetal liver, are also populated by embryonic MSCs [52-54]. These cells
are originally independent of interactions with hematopoietic stem cells and can be found in
the embryonic circulation at early stages of ontogeny [55]. Counterintuitively, a novel
embryological source of MSCs has been identified in the cranial neural crest. Through in
situ methods with fluorescent reporting proteins, one group demonstrated a transient
proliferation of Sox-1 + cells originally from the neuroepithelium that display multipotency
and that transitioned through a neural crest stage to give rise to adult MSCs [56]. Cells with
multilineage differentiation potential and cytoskeletal elements reminiscent of adult MSCs
can be isolated from the first branchial-arch, ectomesenchymal cells that give rise to the
orofacial connective tissue [57-59]. These results are consistent with the promiscuous
expression of neural proteins in MSCs in their basal state [60, 61]. To date, no studies have
determined the genetic events that guide the lineage specification of embryonic precursors
into MSCs. Such genomic profiling can ultimately lead to new ways to derive these cells
from embryonic stem cells or other ontogeny-related cell types.
Although the bone marrow has been established as the primary source of MSCs, because
of the invasive nature of bone marrow aspiration, efforts are underway to identify other
abundant and reliable sources of MSCs for clinical purposes. The isolation of MSCs from
peripheral sources such as umbilical cord blood (UCB) [62, 63], placental tissue [52-54],
and adipose tissue [46] has been reported with cells displaying similar immunophenotypes
and multipotency, although other contradictory studies report the absence of MSCs in
these peripheral locations [64, 65]. Whether there is a definitive relationship between these
cells from various sources is unclear because rigorous studies of in vivo multipotency have
yet to be done. Furthermore, it is important to be wary of interpretations of CFU-F analysis
of MSCs from sites other than the bone marrow, given that many adherent and clonogenic
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fibroblastoid cells exist in nonhematopoietic tissues. Although phenotypically similar, or
even identical in some cases, MSCs derived from different tissues have been shown to
exhibit variable function and activity [66]. It is thought that the MSC niche, unique to each
tissue of origin, is at the root of these variations.
2.3.4. Mesenchymal Stem Cell Localization and Mobilization In Vivo
The physical location, or niche, of a stem cell provides invaluable information about its role
and interactions within the tissue (see Figure 2.2). Bone marrow MSCs have been explored
for therapeutic use more extensively than any other subtype, and the native functions of
these cells in the bone marrow have been studied in hopes of revealing clues about their
therapeutic activity [67, 68]. The MSC niche has been difficult to locate and even harder to
observe dynamically because no unique MSC marker has been identified and because the
marrow cavity is difficult to probe in vivo. That said, based on correlations between
immunophenotype and ex vivo CFU-F assays, evidence supports the idea that MSCs exist
in perivascular locations [69, 70]. This theory is consistent with the observations that (a)
MSCs are presumably found in many tissue types including synovium, periosteum,
adipose, UCB, and placenta [71, 72]; (b) the number of MSCs in a given tissue scales with
the density of microvasculature; (c) MSCs secrete factors that promote vasculogenesis and
endothelial stabilization [73]; and (d) they may exhibit different functional characteristics
depending on the derivative tissue type [66]. Their stromal counterparts may differentiate
and migrate from this space to reside on the albuminal side of marrow sinusoids and form
a three-dimensional network that invests the capillary bed.
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A. Stromal Cell Differentiation B. 'Soluble Factor Secretion
MSC Osteogenesis MSC
Hematopolesis
Adipogenesis
Myeloid Cells Lymphoid Cells
C. Pericytic Function D. ECM Maintenance
MSC
MSC
ECM Proleins
Glycosaminoglycans
Proteoglycans
Figure 2.2 - Natural functions of
mesenchymal stem cells in the bone marrow.
(a) MSCs can differentiate into skeletal tissue
cells within the marrow cavity. (b) MSCs
secrete a number of soluble factors that are
involved in hematopoietic development. (c)
Given their purported perivascular localization,
MSCs may serve cellular functions similar to
pericytes that surround bone marrow
sinusoids. (d) MSCs maintain the mechanical
microenvironment of the marrow by secreting
and remodeling ECM. Abbreviations: MSC,
mesenchymal stem cell; ECM, extracellular
matrix.
Endothelial Cell
Adventitial reticular cells, or percytes, that have fibroblastic extensions projecting into the
lumen of sinusoids, are likely the in vivo surrogate of CFU-F, although single-cell analytical
studies have not been performed [68, 74, 75]. These pericytes share a similar surface and
intracellular protein expression pattern with MSCs, which implies that the cells are
ontologically related [76]. This location has been reproduced in artificial systems as well.
Ectopic stromal cells displaying PDGF-R, NG2, and high expression of CD146 are typically
localized in perisinusoidal regions [77]. In addition, tissue-engineered constructs
juxtaposing MSCs and endothelial cells form long-lasting vascular structures, with MSCs
naturally displaying pericytic phenotype and function [78]. Such localization suggests that
MSCs may be intimately involved in angiogenesis, wound healing, and interactions with
blood-borne entities.
Given their purported perivascular location, the question of whether MSCs mobilize into the
bloodstream during health and disease is an important one that has not been answered. It
is unlikely that bona fide MSCs circulate peripherally because of their limited numbers
(-0.01 % of mononuclear bone marrow cells); it is more likely that they produce lineage-
restricted cell types that home to tissues as a mechanism of nonparenchymal cell
replenishment during injury. Fibrocytes are circulating bone marrow-derived cells (-0.1-
0.5% of nonerythrocytic cells in peripheral blood) that phenotypically resemble a hybrid of
monocytes and fibroblasts expressing type I collagen and the surface markers CD1 1 b,
CD13, CD34, and CD45RO [79]. In sex-mismatched bone marrow chimeras, these cells
were found to be the progeny of a radioresistant precursor from the bone marrow [80].
During injury, fibrocytes were rapidly and specifically found in the areas of inflammation
[80], fibrosis [81], and cancer [82-85], where they are thought to mature into tissue-resident
myofibroblasts [86]. They express chemotactic receptors such as CCR3, CCR5, CCR7,
and CXCR4 and are absent of CCR4, CCR6, and CXCR3 [79]. Interestingly, fibrocytes
express surface molecules such as major histocompatibility complex class 11, CD80, and
CD86 and were shown to present pulsed antigens to naive T cells in an efficient manner
when compared with monocytes and dendritic cells, although this was not verified in vivo
[87]. These cells have functional and phenotypic resemblance to bone marrow resident
MSCs; therefore, refining current theories to distinguish the MSC-fibrocyte axis may lead to
a greater understanding of each cell type during health and disease.
2.3.5. The Interaction between the Bone Marrow Stroma and
Hematopoiesis
MSCs exist within the bone marrow as a precursor to connective-tissue components that
act primarily as supportive elements to hematopoiesis. The essential functions of MSCs
and their precursors within the marrow can provide insight into mechanisms involved when
these cells are used in a therapeutic context. The initial appreciation for the important
interaction between stromal cells and hematopoietic cells was obtained from the analysis
of two different spontaneous mutations in mouse colonies that led to the same anemic
phenotype. Analysis of these mutant mice revealed that a stromal cell ligand known as
stem cell factor (SCF) and its associated receptor, c-kit, found on hematopoietic stem cells
(HSCs) was essential for the maintenance of HSCs. Other cell-cell interactions between
MSC progeny, such as osteoblasts and HSCs, have also proved essential for HSC self-
renewal [88, 89]. Moreover, stromal elements secrete a number of insoluble and soluble
species within the marrow space that promote the growth and differentiation of
hematopoietic cell lineages [90-93].
Experimentally, MSCs can act as a surrogate feeder layer and promote the self-renewal
and differentiation of HSCs in long-term colony-initiating culture and CFU assays [94]. Two
types of culture techniques utilizing stromal cell layers and defined chemical supplements
allow for the establishment of lymphoid and myeloid cells in vitro. The Whitlock-Witte
method cultures bone marrow cells on a confluent layer of irradiated stromal cells with a
low-serum-containing medium without corticosteroids [95, 96]. It is a lymphoid culture
system, which supports the growth of B lymphocytes and which, with some modifications
in culture parameters, can also allow selective proliferation and differentiation of all
developmental stages of pre-B cells and B lymphocytes. A myelopoietic culture system,
known as Dexter cultures, maintains myeloid progenitor cells and differs from Whitlock-
Witte cultures by using high concentrations of serum and hydrocortisone and lower
incubation temperatures [97, 98]. Collectively, the marrow stroma can direct the
differentiation of lymphoid and myeloid cells in vitro, and it is likely that the mechanisms
underlying this directed differentiation will be relevant to the immune response to MSCs in
vivo.
2.4. Preclinical and Clinical Applications of Mesenchymal Stem
Cell Therapy
An extra level of biological understanding is often gained during testing of a new
therapeutic. The evolution of MSC therapy over the years reflects a transformation in how
investigators view these cells and their best-suited clinical applications. Initially heralded as
stem cells, MSCs were first evaluated for regenerative applications. MSCs have since been
shown to directly influence the innate and adaptive arms of the immune system [99],
enhance proliferation of epithelial cells [100], and promote neovascularization of ischemic
tissues [73]. These observations have prompted a new age of MSC transplantation as a
treatment for immune-mediated and tissue-sparing diseases. In this section, we capture
this paradigm shift and focus on important studies that contextualize MSCs as a
therapeutic for regenerative medicine and inflammatory diseases. Furthermore, we discuss
the potential side effects that should be considered when MSCs are used.
2.4.1. Mesenchymal Stem Cells for Regenerative Medicine and
Inflammatory Diseases
MSCs are currently being explored for use in humans because of their potent ability to treat
many devastating diseases in animals (see Table 2.3). Although the primary mechanisms of
action have not been fully elucidated, studies indicate that MSCs can act on several levels
of endogenous repair to bring about resolution of disease. MSCs have been shown to
protect cells from injury and directly promote tissue repair [101, 102]. When administered to
treat animals undergoing acute kidney injury, MSCs prevent apoptosis and elicit
proliferation of renal-tubule epithelial cells in a differentiation-independent manner [103-
105]. When injected into the myocardium after infarction, MSCs can reduce the incidence
of scar formation [106-108]. When administered to prevent the onset of IDDM, MSCs
protect p-islets from autoimmune attack; when administered after onset of the disease,
they promote temporary restoration of glucose regulation, suggesting protection and repair
of damaged islet tissues [109].
Table 2.3 - Animal studies of diseases shown to respond to administration of mesenchymal stem cells
Disease Animal Model(s) Method of Administration Evidence of MSC Efficacy Ref.
Acute Kidney Injury
Myocardial Infarction
Type I Diabetes
Mellitus
Graft vs. Host Disease
Systemic Lupus
Erythrematosus
Acute Disseminated
Encephalomyelitis
(Multiple Sclerosis)
Pulmonary Fibrosis
Rodent
Cisplatin
Ischemia/ reperfusion
Rodent
LAD ligation
Pig
Temporary LAD occlusion
Rodent
Intravenous infusion
Intravenous infusion
Intramyocardial
transplantation
Intravenous infusion
NOD mice
Streptozotocin
Rodent
HLA-misrnatched bone
marrow transplantation
Rodent
MRLApr mouse
Rodent
Experimental Autoimmune
Encephalornyelitis,
Rodent
Bleomycin induced lung
injury
Intravenous infusion
Intravenous co-infusion
with bone marrow
transplant
Intravenous infusion
Intravenous infusion
Intravenous infusion
Decreased serum creatinine
Decreased apoptosis
Increased epithelial proliferation
Suppression of pro-inflammatory
cytokine gene expression
Reduction in scar formation
Improvement in cardiac function
Differentiation of MSCs into
functioning myocardium
Partial restoration of glucose
management
Reduction in anti-insulin T cells
Prevention of FOXP3+ cell
apoptosis
Increased survival
Recapitulation of bone marrow
osteoblastic niche
Reduction in autoantibody levels
Improvement in kidney function
Reduction in ANA
Increase in FOXP3+ cells
Improved clinical score
Reduced demyelination
Reduced immune cell infiltrate into
CNS
Reduced inflammation
Reduced collagen deposition
Reduced MMP activation
"Abbreviations: ANA, anti-nuclear antigen; CNS, central nervous system; LAD, left
human leukocyte antigen; MMP, matrix metalloproteinase.
anterior descending; NOD, nonobese diabetic; HLA,
[104,
105,
110-
112]
[106-
108,
113,
114
[109,
115-
118]
[119,
120]
[121]
[122-
124]
[101,
102]
In addition to promoting tissue repair directly, MSCs have also been shown to modulate
the immune system and attenuate tissue damage caused by excessive inflammation. Initial
indications regarding the immunomodulatory aspects of MSCs were first observed in the
context of MSC transplantation studies in animals and humans. Unexpectedly, MSCs
seemed to exhibit an unusual ability to evade the immune system. Initial clinical trials
showed that autologous and allogeneic MSCs could be transplanted without immune
rejection [35, 37]. Further preclinical studies presented similar findings: Human MSCs can
engraft and persist in many tissues in prenatal and adult sheep with no apparent rejection
[125]; MSC injection in baboons can prolong the life of a transplanted skin graft and
suppress T cell proliferation in a dose-dependent manner [126]; and injected MSCs can
suppress the immune response in mice, allowing for the expansion of tumor cells [127]. The
immunosuppressive ability was first exploited clinically in the treatment of an 8-year-old
boy with severe, acute GvHD, who was refractory to steroid immunosuppression [128]. The
patient was successfully treated by MSC transplantation. In recent years, this
immunosuppression has been found to be an active process, and the mechanisms
underlying MSC immunomodulation operate at different levels of the innate and adaptive
immune system.
2.4.2. Decomposing the Interaction between MSCs and the Immune
System
Many studies suggest that MSCs can promote the conversion from a TH1 (cell-mediated)
immune response to a TH2 (humoral) immune response (Figure 2.3) [99]. In vitro coculture
experiments have been used to exemplify the effects of MSCs on individual populations of
immune cells that favor this conversion at the cellular and molecular levels. With respect to
adaptive immunity, the majority of in vitro studies have shown that MSCs can directly
inhibit CD3+, CD4+ T cell proliferation and secretion of TH1 lymphokines, such as IL-2 and
IFN-y. These studies have induced T cell activation by various methods including mixed
lymphocyte reactions (MLRs), mitogens, and T cell receptor (TCR) or costimulatory
receptor engagement. T cells in the presence of MSCs appear to be anergized by the lack
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of a second danger signal by MSCs, which do not express the costimulatory molecules
CD80, CD86, and CD40 [129]; however, this has yet to be definitively proven.
TH1 to TN2 Conversion
Proliferation of T r
IL-10 from Treg
Ig Production
Plasma Cell Differentiation
B Cell
Maturation
Expansion
IL-1 2 Secretion
IFN-y Secretion
TNF-a. Secretion
DC 1/
T Cell
Proliferation of Effector Cells
CTL Formation
IFN-y Secretion
IL-2 Secretion
NK Cell
MSC
Proliferation
IFN-y Secretion
Cytotoxicity
NKp30 Expression
NKG2D Expression
Proliferation
IL-10 Secretion
DC 2
9 Promotet TInhibit
Figure 2.3 - Summary of MSC interactions with select immune cells. Abbreviations: TH1, helper type 1 T
cell; TH2, helper type 2 T cell; Tr, regulatory T cell; IL, interleukin; CTL, cytotoxic T lymphocyte; IFN- y,
interferon-y; NK, natural killer, DC 1, type 1 dendritic cell; DC 2, type 2 dendritic cell; TNF-a, tumor necrosis
factor-a; Ig, immunoglobulin. Partially adapted from [130].
Several investigations have also shown a direct suppressive effect of MSCs on cytotoxic
CD8+ T cells. MSCs prevented cytolysis of target cells by alloantigen-specific CD8+ T cells
when present during the priming of cytotoxic cells [131]. Some investigators attribute the
inhibition of cytotoxicity by MSCs to an intrinsic "veto" function or to the generation of
suppressor CD8+ cells after coculture [132], although conflicting data exist. Other reports
have also observed generation of CD4+ CD25+ T cells, a cell-surface-marker expression
pattern of both newly activated CD4+ lymphocytes and regulatory T cells [133]. Although it
is unclear whether MSCs directly influence B cells in vivo, some in vitro evidence suggests
that MSCs can suppress B cell proliferation [134, 135]. In contrast, other reports have
shown that MSCs can stimulate antibody secretion and induce polyclonal differentiation
and expansion of healthy human B cells [136, 137], consistent with the supportive role of
stromal cells in B lymphopoiesis. In addition, these same supportive mechanisms may
advance the progression of B cell-mediated disease such as multiple myeloma and
systemic lupus erythematosus [138]. However, it is possible that suppression of T cells by
MSCs may contribute to decreased B cell activity in vivo [139].
The switch from a cell-mediated to humoral immune response triggered by MSC
transplantation may involve the differentiation of innate immune cells to an anti-
inflammatory phenotype. Within an inflamed tissue environment, MSCs are capable of
influencing many aspects of the cytotoxic responses to injury and disease [140]. MSCs can
attenuate natural cytotoxic responses of neutrophils by dampening respiratory burst and
inhibiting spontaneous apoptosis in vitro via secretion of IL-6 [141]. MSCs also possess the
ability to suppress proliferation of natural killer (NK) cells [142-144] and attenuate their
cytotoxic activity by downregulating the expression of NKp3O and NKG2D, surface
receptors involved in NK cell activation [145]. This is accomplished even while cytokine-
activated NK cells are capable of killing MSCs in vitro, suggesting a possible mechanism
for MSC rejection in vivo [142]. In vivo studies have yet to be performed to demonstrate this
mechanism. MSCs can also revert macrophages to adopt an anti-inflammatory phenotype
in the context of sepsis by secreting prostaglandin E2 and conveying a contact-dependent
signal to promote IL-1 0 secretion [146].
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Dendritic cells (DCs) serve as the major link between innate and adaptive immunity
because of their ability to present antigens to lymphocytes with high efficiency. In coculture
with MSCs, monocytes failed to differentiate into DCs when cultured in lineage-specifying
growth conditions [147, 148]. In addition, MSCs inhibited the maturation of DCs to present
appropriate antigens and costimulation to T cells through CD1 a, CD40, CD80, CD86, and
HLA-DR [147, 149]. After coculture with MSCs, DCs were ineffective in their ability to
activate lymphocytes by suppressing TNF-a and IFN-y expression and upregulating IL-10
in DC-CD4+ MLRs [130, 148]. This interaction was found to be y-secretase dependent,
indicating the role of the Notch pathway in MSC-DC interactions [150]. Ultimately, MSCs
may drive, or "license," DCs to a suppressor phenotype that can further attenuate T celk
mediated immunity.
2.4.3. Potential Side Effects of Mesenchymal Stem Cell Therapy
MSC transplantation has been designated safe by the FDA. Thus far, clinical trials of MSC
transplantation have shown no adverse events that affected the safety profile of these cells
over the past 10 years of testing. Nevertheless, recent preclinical studies have highlighted
potential long-term risks associated with MSC therapy that may not be observable in the
short time period following administration (see Figure 2.4). These risks include potential
maldifferentiation, immunosuppression, and instigation of malignant tumor growth.
Figure 2.4 - Potential risks associated with
MSC transplantation. (a) MSCs have been
shown to maldifferentiate into glomerular
adipocytes and osteosarcomas when
administered systemically. (b) Systemic
administration of MSCs may impair immune
surveillance, making the recipient more
susceptible to opportunistic infections. (c)
When transplanted with cancer cells, MSCs
can adapt a tumor-associated fibroblast
phenotype and support the growth of the
cancer by directly promoting tumor growth,
metastasis, and angiogenesis. Abbreviations:
MSC, marrow stromal cell; TAF, tumor-
associated fibroblast.
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MSCs are multipotent cells and may ectopically differentiate after therapeutic
transplantation. Recent animal studies have confirmed that this is possible. MSCs, when
administered in the context of acute glomerulonephritis in rats, can engraft in the renal
tubules and maldifferentiate into adipocytes that hinder normal function of the kidney and
lead to chronic kidney disease [151]. When administered in mice, MSCs can also create
microemboli and subsequently form osteosarcoma-like pulmonary lesions [152]. However,
this phenomenon has been observed in immunocompromised mice and therefore may not
reflect a considerable risk to immunocompetent hosts. A similar observation was made
when MSCs were administered to nonobese diabetic (NOD) mice in the context of IDDM
[109]. The MSCs formed soft tissue and visceral tumors throughout the mice upon
administration. These studies may indicate risks of MSC transplantation that may be of
particular importance to immunocompromised patients.
Healthy Lung
Other potential complications of MSC transplantation are related to the
immunosuppressive properties of these cells and the loss of immunosurveillance to foreign
and host pathogens. After MSC infusions were used to treat nine patients suffering from
GvHD, three developed viral infections [153]. Although these patients were at increased risk
for developing opportunistic infections through the nature of their disease, concerns were
raised that immunosuppression by the MSCs had caused a reduction of
immunosurveillance to viruses.
These findings are supported by in vitro observations that lymphocyte proliferation by
herpes viruses is suppressed by MSCs [153]. Cancer is another potential serious side
effect. Theoretically, MSCs could be tumorigenic through direct transformation, metabolism
of chemotherapeutic agents, and/or suppression of the antitumor immune response. All
these phenomena have been reported previously. MSCs have the potential to transform
into sarcomas when Wnt signaling is suppressed [154]. Mesenchymal cells have been
shown to regulate the response of acute lymphoblastic leukemia to asparaginase
chemotherapy by metabolizing the drug via their high expression of asparaginase
synthetase [155, 156]. Marrow stromal cells, highly enriched for MSCs, promote survival of
B- and plasma-cell malignancies by inducing hedgehog signaling [157]. Moreover, MSCs
used for the treatment of GvHD limited the graft-versus-leukemia effect of allogeneic bone
marrow transplantation, leading to a higher rate of relapse compared with control groups
[158, 159]. Patients with increased risk of malignancy or opportunistic infections may not
be suitable candidates for MSC therapy; researchers should take this into account when
assessing trials until more conclusive experimental data become available.
MSCs also associate with tumors and promote tumor growth when administered
systemically into animals with existing malignancy [160, 161]. Animal studies by Djouad
and colleagues have revealed enhanced tumor growth after MSC transplantation when
tumor cells were implanted [127, 162]. It is unclear whether the MSCs enhanced tumor
growth by immunomodulatory, trophic, or other effects. Karnoub et al. demonstrated that
MSCs within tumor stroma promote breast cancer metastasis via cancer cell-induced de
novo secretion of the chemokine CCL5 in MSCs [161]. Recent work has shown that MSCs
can differentiate into tumor-associated fibroblasts (TAFs) that provide stromal support to
growing tumors [163]. When mixed with tumor cells and transplanted in vivo, MSCs fulfill
the following four criteria that are required for them to be considered TAFs: (a) expression
of fibroblast markers FAP and FSP; (b) secretion of neovascularization promoters VEGF,
desmin, and a-smooth muscle actin; (c) secretion of tissue remodeling and invasion
proteins TSP-1, Tn-C and SL-1; and (d) secretion of tumor-promoting factors hepatocyte
growth factor (HGF), epidermal growth factor (EGF), and IL-6 [163]. It should be noted,
however, that the number of MSCs mixed with the cancer cells exceeded a typical
systemic dose, and therefore they may represent a risk only if excessive numbers of MSCs
are administered. Although MSCs were not specifically demonstrated to arise from the
bone marrow in these studies, evidence that MSCs possess the ability to differentiate into
TAFs is consistent with other studies showing that mesenchymal stem cells are recruited to
the sites of indolent tumors and promote growth [164]. Osteopontin is implicated as one of
the key hormonal mediators of this effect, and it has been shown to be secreted by MSCs
that have begun to differentiate down the osteoblast lineage [91]. Future studies will be
required to demonstrate direct causality.
Interestingly, some investigators are using the "tumor-homing" properties of MSCs for
therapeutic use by genetically engineering the cells with cytolytic drugs to kill tumorigenic
tissue selectively [165]. MSCs that are genetically engineered to express TRAIL, a ligand for
death receptors on the surface of tumor cells, can suppress tumor growth among
subcutaneous tumors, pulmonary metastatic tumors, and highly malignant glioblastoma
tumors in mice [166, 167]. Also, MSCs engineered to deliver IFN-p are capable of migrating
into the brain and providing survival benefit to mice with gliomas [168]. Using the homing
properties of MSCs as such may present a new opportunity for use of MSCs as drug
delivery vehicles in the context of cancer.
2.5. Molecular Particle Theory of Mesenchymal Stem Cell Therapy
Therapeutic studies in different injury models accompanied by cell-tracking studies have
revealed two peculiar observations: First, infusion of undifferentiated MSCs leads to
therapeutic effects in different injury models without MSC differentiation. Second, the
majority of MSCs cannot be located by sensitive, whole-body imaging techniques days
after transplantation. In this section, we discuss studies that suggest that MSCs may impart
therapeutic benefit by secreting soluble factors, and then we paint a molecular portrait of
MSCs. Next, we highlight particular biodistribution studies that describe the rapid kinetics
of MSC clearance after transplantation similar to what might be found when inert particles
are injected. Finally, we close with a new proposed framework for pharmacokinetic analysis
of MSC therapy.
2.5.1. Molecular View of Mesenchymal Stem Cells
Recent work has shown that the therapeutic benefits observed when MSCs are
transplanted can be completely recapitulated, and in some cases improved upon, by
administration of MSC secreted factors alone. This is not surprising because suppression
of effector functions in most MSC-immune cell coculture studies was reproduced in the
absence of cell-cell contact and in a dose-dependent manner, indicating the role of soluble
factors. Furthermore, these inhibitory molecules can exert their effects across species
barriers as evidenced by suppression of MLRs in xenogeneic cultures [169]. MSC-
conditioned supematants have no antiproliferative effect on T cells, yet they are capable of
suppressing the stimulation of B cells [134]. This suggests that MSCs can dynamically
react to their immunological environment in the context of T cells while also secreting
immunomodulatory molecules in their quiescent, undifferentiated state in the context of B
cell development. Also, the numbers of MSCs needed to suppress T cell activity compared
with B cell activity differ by approximately one to two orders of magnitude [135, 170]. These
studies hint at the interesting dynamics and dosing of MSC-derived molecules that
researchers should consider when evaluating MSC therapeutic applications.
It remains highly debated as to which soluble mediators are involved in MSC therapy
(reviewed in Reference [171]), although a clear distinction can be made that some
molecules are considered naturally secreted by MSCs and others are inducible. Many
candidates such as HGF, transforming growth factor P, (TGF-p1), or the metabolic
byproduct of indoleamine 2,3-dioxygenase (IDO) [99, 172-176] are basally secreted by
these cells. However, stimulation of MSCs by toll-like receptor ligands or inflammatory
cytokines causes an alteration of the MSC secretome and a different set of chemical
species [177, 178]. For example, lipopolysaccharide (LPS) found in serum leads to the rapid
upregulation of prostaglandin F2 (PGE,), likely through an immediate early gene response
related to NF-KB. Recently, researchers demonstrated a direct correlation between the
upregulation of an anti-inflammatory protein, TSG-6, upon engraftment of MSCs in the
lungs and the recovery of myocardial function after infarction [14].
In our laboratory, we have sought to leverage this collection of bioactive molecules to treat
animals undergoing inflammatory organ injury. We have developed methods for
intravenously administering MSC-derived molecules in the form of concentrated
conditioned medium, as well as in a dynamic and continuous manner by using an MSC
extracorporeal bioreactor. Initially, it was our intent to treat rats undergoing D-
galactosamine-mediated organ injury by transplanting human MSCs. However, upon
transplantation of the cells, we observed no benefit to the animals as measured by 7-day
survival [41]. In contrast, by systemically administering the equivalent mass of lysed cells,
we observed a survival trend, suggesting that the molecules relinquished upon lysis provide
the primary benefit. We confirmed this hypothesis by collecting the molecules secreted in
MSC conditioned medium (MSC-CM) and administering a concentrated form of MSC-CM
intravenously in a single bolus dose to animals after the induction of disease. We found that
MSC-CM provides a statistically significant survival benefit, causing an increase in survival
from 14% in our control groups to 50% in our treatment group [42]. We then engineered a
delivery platform for the continuous and dynamic administration of these molecules into the
bloodstream [41] and found that this treatment method provided an improved survival
benefit of 71 % compared with 14% in controls.
These studies collectively suggest that the soluble factors of MSCs account for the majority
of beneficial effects in response to MSC transplantation. Considering the putative natural
functions of MSCs, it is reasonable to postulate that the same secretory mechanisms by
which MSCs maintain hematopoiesis are therapeutic in the context of disease. In fact,
many of the MSC factors that have been implicated in hematopoiesis have also been
shown to provide therapeutic benefit in certain disease models. Many insist that upon
transplantation of the cells, engraftment, proliferation, differentiation, and homing to the site
of injury are equally important. However, new evidence is suggesting that MSC
engraftment rarely occurs, and observed therapeutic benefits of MSC transplantation may
arise from other altemative explanations.
2.5.2. Particle View of Mesenchymal Stem Cells
Early qualitative studies using MSCs stably transfected with a fluorescent reporter gene for
bone regeneration revealed interesting dynamics of the MSC grafts in vivo. First,
engraftment of osteoprogenitor cells was found to be saturated, suggesting that higher
doses of cells would be an ineffective strategy to improve engraftment [179]. Second,
temporal tracking of enhanced green fluorescent protein (eGFP)-expressing MSCs showed
that transplanted cells exhibited limited proliferation and self-renewal capacity after
engraftment, yet they could be serially passaged and repopulate another host [180]. Similar
studies have evaluated different reporter strategies, but most techniques used are not
amenable to whole-subject imaging by nature and thereby may be confounded by
selective tissue sampling.
Quantitative examination of the biodistribution of MSCs within the body after
transplantation suggests that the dynamics of an MSC graft are similar to that of inert
micrometer-scale particles injected into the blood stream of animals [181]. Recent studies
using sensitive cell-tracking methods have revealed these counterintuitive results (Figure
2.5). Most homing and engraftment studies have demonstrated little, if any, long-term
engraftment (>1 week) of MSCs upon systemic administration. Studies have shown that the
majority of administered MSCs (>80%) accumulate immediately in the lungs and are
cleared with a half-life of 24 h [14, 182, 183]. Tissue-specific homing has been
demonstrated, indicating a response of the administered MSCs to injured tissue [184]. It
was shown in a mouse model of myocardial infarction that MSCs are capable of engrafting
in the site of injury and differentiating into cardiomyocyte-like cells that were shown via
immunohistochemistry to express typical cardiomyocyte markers [185]. Another study
showed that in mice undergoing cisplatin-mediated acute kidney injury, systemic injection
of MSCs resulted in accumulation of MSCs in the kidney and differentiation into tubular
epithelial cells that exhibited the characteristic brush border of the proximal tubule [186].
Nevertheless, the majority of studies have shown that only a small percentage of the
original systemically administered cell mass is capable of engrafting even under the best
conditions, and of those that do engraft, only a small percentage have been shown to
differentiate into functional replacement tissue.
These homing, engraftment, and differentiation studies illustrate one of the most persistent
paradoxes in MSC therapy: Systemically administered MSCs appear to convey potent
therapeutic responses in a variety of diseases, and yet they have not been shown to exhibit
long-term engraftment. Adding further complexity, recent studies have suggested that
allogeneic MSCs are not immunoprivileged, that they enjoy a only minimally prolonged
residence time compared with allogeneic fibroblasts [15], and that they may elicit a memory
response leading to a rapid clearance of subsequent doses by the immune system. It is not
unreasonable to suggest, therefore, that instead of engrafting and differentiating, MSCs
convey therapeutic benefit by relinquishing their molecular contents. In this way, MSCs
may be better viewed as drug delivery particles that, when administered, are subject to
distribution and clearance similar to other intravenous therapeutics. Therefore, if the cells
are to be delivered optimally, quantitative analysis regarding their pharmacokinetics will
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better inform dosing regimens to account for the limits and advantages of particle drug
delivery as such.
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Figure 2.5 - Representative studies
describing the in vivo distribution of
MSCs upon systemic administration.
Tracking studies generally consist of
intravenous injection of the cells and
then tracking of the cells using a
variety of known methods. The
representative studies featured here
used two sensitive methods available
for whole-organism analysis:
polymerase chain reaction of a
human gene to quantify human MSC
engraftment in a number of mouse
tissues, and MSCs labeled with
luciferase to qualitatively trace their
engraftment. Abbreviation: iv,
intravenous.
2.5.3. The Pharmacokinetics of a Mesenchymal Stem Cell Graft
A reductionist view of MSCs as particles loaded with a molecular drug may enable efforts
to predict the efficacy of this cellular therapeutic within the confines of known physical
models of drug delivery systems. By extracting quantitative parameters from retrospective
studies, we plan to take a mathematical approach to propose designs of new formulations
and dosing regimens composed of MSC therapy. The objective of this exercise is to
maximize the therapeutic activity of MSCs while minimizing potential side effects
associated with MSC transplantation such as maldifferentiation and tumor growth.
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As with most physical models, we make a few basic assumptions and approximations to
simplify the problem in order to display analytical solutions. It would perhaps be more fitting
to use computational approaches to solve the complex set of partial differential equations
that form the basis of this theory, but doing so would exceed the scope of this initial model.
We begin by modeling MSCs as inert, spherical (d = 20 [im) particles that have no
interactions with host structures. Furthermore, we assume that a single molecule of fixed
concentration is encapsulated within each MSC and contains 100% of the bioactivity. The
transport of this single molecule from the cell directly into the bloodstream is not rate
limiting. Finally, we assume that a defined therapeutic index exists with respect to the
single molecule that directly correlates to serum concentration profile.
With these assumptions in place, we first consider the cell mass used in clinical studies and
employ order-of-magnitude approximations to determine if the current clinical dosing of
MSCs is justified. If cells secrete -100 pg 10- cells per day of a therapeutic mediator,
which corresponds to -0.1 fg per cell (assuming the same intracellular levels of the
mediator), then we can estimate that when a clinical-scale mass of MSCs (-100 x 106 cells)
is infused intravenously, this equates to -10 ng of a therapeutic molecule. In comparison
with other biologics, which are administered in the microgram to milligram range, we can
immediately see that the clinically administered dose of molecules relinquished from MSCs
is at least -two to three orders of magnitude lower than that of other single-molecule
therapeutics. This simple analysis would suggest that a greater cell mass should be
administered, but it does, of course, grossly underestimate the biological complexity of the
molecular mixture composed within MSCs, which is multifactorial in nature and may have
synergistic effects.
With respect to the temporal dosing of an MSC graft, we have taken known kinetics data
concerning MSC transplantation from selected studies [14, 15] and have represented these
data in a new form to illustrate this concept graphically (Figure 2.6). In the extreme case,
and perhaps consistent with early notions, effective MSC transplantation assumed that
nearly 100% of the cells remain viable and active after infusion into a subject. Therefore,
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the units of activity of the transplant would approach steady state in the timescale of days
to weeks after administration. However, if we plot the normalized cell concentration found
in tissues within 1-120 h based on previous studies, we see that the kinetics of an MSC
graft is much more transient than expected with a half-life of approximately 24 h. Using a
two-compartment pharmacokinetic model, we can extract parameters that explain the
discrepancy between theoretical and apparent bioavailability of MSCs. Assuming an
intravenous bolus where the infusion rate (R) is eliminated and the dimensionless plasma
concentration Cp(t = 0) is equal to 1, we find that the rate of tissue intravasation (K) and the
rate of clearance (Re) are significantly greater than the theorized tissue extravasation (K,),
resulting in a much shorter half-life of the cellular therapeutic. Furthermore, we see that the
apparent activity of the treatment, represented as the time to reach maximal secretion of a
molecular mediator, is extremely sensitive to the cellular viability and reinforces the concept
of a short therapeutic window associated with MSC therapy. If we arbitrarily choose a
minimum effective concentration of MSC therapy and transpose this timescale to a
biological response, we see that transplanted MSCs are only therapeutically active for a
short period of time (in this case, less than 24 h). This timescale corresponds precisely with
measured serum cytokine levels that are directly associated with MSC therapy [146] and
that potentially can be considered surrogate biomarkers for effective therapy. Ultimately,
successive doses of MSCs within a shorter treatment period may allow for the
maintenance of MSC therapy within a therapeutic window that can ultimately sustain a
long-term biological response.
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to be sustained thereafter. (c)Apparent engraftment of MSCs with a decaying retention of MSCs. Assuming
an exponential decay with a 24-h half-life, the apparent activity peaks above the minimum effective activity
level only for a brief period of time. This results in a brief and temporary biological response that does not
persist beyond 24 h. These data are consistent with cytokine response associated with MSC transplantation
or MSC-derived molecules when the latter were administered to animals undergoing systemic inflammation.
2.6. Conclusions
Developing new therapies that affect multiple disease pathways is of growing importance
for patient care. MSC transplantation represents an exciting approach that could potentially
treat complex diseases by providing combinatorial therapy. Furthermore, the continued use
of MSC therapy can be recast to better our understanding of the natural role of these cells
during health and disease in vivo. The collected efforts of scientists, engineers, physicians,
and industry will be necessary to realize the promise of MSC therapy.
Optimization of MSC therapy may not be achievable until the primary mechanism(s) of
action afforded by intravenous administration of MSCs is determined. Current optimization
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Figure 2.6 - Pharmacokinetic analysis of
MSC therapy. (a) Schematic of two-
compartment pharmacokinetic model of MSC
drug delivery incorporating the following
parameters: Ri, injection rate; Rc, clearance
rate; K1, rate of extravasation; K2, rate of
intravasation. (b) Theoretical engraftment of
MSCs with a hypothetical retention of nearly
100% of MSCs over the course of 120 h. The
apparent activity is the product of the unit
activity per cell and the number of cells
remaining after injection. Assuming a
minimum effective activity level well below the
apparent activity, the biological response
would be expected to rise as soon as the
minimum effective activity level is reached and
approaches are based on the number of MSCs used, but this parameter alone may not
capture the true activity of this complex therapy. The therapeutic activity of an MSC graft
was once thought to be a function of engraftment and differentiation. However, mounting
evidence is indicating that MSCs can impart activity independent of these functions.
Trafficking studies have reported that systemically administered MSCs fail to engraft in
most tissues and that engrafted cells may eventually be rejected, resulting in immunological
memory to subsequent treatments [14, 15]. This new evidence suggests that the activity of
MSC formulations may have half-lives on the order of an inert particle. This timescale
should be considered when new dosing regimens for MSC therapy are being defined.
To simplify the explanation of cellular biodistribution, we have considered MSCs as inert
particles. However, in reality they are by no means inert. Bone marrow MSCs actively
participate in the maintenance of hematopoiesis and therefore influence the development
of cells in the immune system. MSCs can differentiate into stromal lineages that provide the
cellular and structural elements required to support hematopoiesis. Beyond cellular
differentiation, MSCs fortify the chemical milieu of the bone marrow by secreting many
immunoregulatory and trophic factors that contribute to the successful development of the
blood cells. In essence, MSCs are intimately associated with homeostatic mechanisms that
tightly regulate activity in the bone marrow microenvironment. As a consequence, MSCs
may be naturally equipped to interact directly with the immune system and influence it by
mechanisms that are concordant with the origins of MSCs. Indeed, the natural target tissue
of MSC therapy may very well be the hematopoietic system.
By using previous examples of molecular therapeutics as an initial framework, we have
attempted to describe the theoretical behavior of MSCs upon administration in order to
identify some options to consider when developing dosing regimens. Using our simplified
model, we can glean that cell therapy may need to be administered at a greater magnitude
and/or frequency to sustain a long-term biological response. Moreover, methods that
improve the half-life of the graft in vivo by increasing cell survival and engraftment or by
decreasing cell clearance may also be viable options to enhance therapeutic activity.
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Furthermore, this model underscores the need to identify these mechanisms that govern
cell fate in vivo as well as practical and relevant biomarkers that can be used to monitor the
activity of MSCs after administration.
MSCs have the potential to treat many unmet medical conditions that afflict patients every
day in a manner that is consistent with the human body's natural capacity to heal itself.
Development of quantitative means for harnessing the source of MSC therapeutic activity
will therefore ensure we make the most of everything these cells can accomplish.
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3. Leveraging Mesenchymal Stem Cell Secretions for
Therapy
3.1. Introduction
In the last chapter, we reviewed the state-of-the-art of MSC therapeutics, from in vitro
findings, animal models of disease, and MSC transplantation in human subjects. In the
final sections of the chapter we began to hint at the limitations in the field currently in terms
of a lack of understanding of the mechanisms of action of MSC transplantation, especially
as it pertains to the pharmacokinetics of MSC grafts. In this chapter we will describe our
work with MSC secreted factors, which we have found to exhibit potency and efficacy
comparable to, and in some cases superior to MSC transplantation. We will begin by
presenting the results of our studies wherein we tested the therapeutic benefit of MSC
conditioned medium (MSC-CM) to treat rats with acute kidney injury (AKI). Then, as the
next step towards translating the delivery platform for MSC secreted factors into clinical
use, we will describe our work in developing a clinical-scale bioreactor for use in large
animals and patients with AKI.
Before we begin, however, I want to introduce various concepts that will be relevant to the
results reported, with a particular focus on acute kidney injury.
3.1.1. Etiology, Clinical Definition and Pathophysiology of Acute Kidney
Injury
Acute kidney injury (AKI) is a devastating syndrome that accounts for hundreds of
thousands of deaths annually worldwide [187]. Despite advances in patient management
and renal support therapy technologies, this devastating mortality has not significantly
changed in the last 50 years; even with the best treatment available, the mortality
associated with AKI is as high as 70% among patients receiving dialysis. Generally
characterized by a reduction in glomerular filtration rate (GFR), AKI has many root causes
(Table 3.1.1) [188-196]. The most common cause of AKI is renal ischemia, occurring in over
50% of patients with AKI.
Table 3.1.1 - Causes of AKI and the Pathological Manifestations
Causes of AKI Incidence Pathological Manifestation
Hypovolemia Necrosis, Apoptosis of Tubules
Vascular occlusion Necrosis, Apoptosis of Tubules
Sepsis ~60% Necrosis, Apoptosis of Tubules, Nephritis
Drug (radiocontrasts, microbials, Necrosis, Apoptosis of Tubules
chemotherapeutics) Nephritis
Hepatic dysfunction
Primary renal disease ~25-35% Necrosis, Apoptosis of Tubules, Nephritis
Impaired renal perfusion Necrosis, Apoptosis of Tubules
Obstruction of the collecting system -5-15% Necrosis, Apoptosis of Tubules
The clinical definition of AKI varies. In general, AKI is characterized by an abrupt loss of
renal function, resulting in electrolyte misbalance, failed waste excretion, an inability to
concentrate urine, and a loss of fluid regulation [190]. Specifically, AKI often is associated
with a reduction in renal blood flow from increased renal vascular resistance, a decrease in
the ultrafiltration coefficient, and/or tubular obstruction [197].
Because the etiology of AKI is varied, the complete pathophysiology of AKI is case-
dependent. It is thought that there are nearly 50 different pathophysiological pathways that
describe the onset of AKI [192]. Nevertheless, most instances of AKI share certain
hallmarks that are characteristic of the disease regardless of cause. Generally, AKI entails
the rapid decline of kidney function over the course of hours to days. This is often the result
of either: (1) a significant decrease in renal perfusion; or (2) toxic damage to the
parenchyma of the organ. In the case of decreased renal perfusion, hypoxia inhibits
oxidative phosphorylation, depleting the organ of energy, and induces a pro-inflammatory
state in the organ by stimulating the vascular endothelium and resident leukocytes [198,
199]. Also, depending on the perfusion state, low renal perfusion can activate the renin-
angiotensin system (RAS), resulting in vasoconstriction of the afferent and efferent
arterioles, exacerbating the impaired blood flow. The resultant ischemia leads to a loss of
function in the tubule epithelia, precipitating failure to properly maintain electrolyte
homeostasis, fluid balance, blood pH, and excretion of metabolic wastes, in addition to
further activation of the epithelium, endothelium and resident leukocytes. A combination of
impaired oxygen delivery; accumulation of metabolic wastes; and up-regulation of
inflammatory cytokines, reactive oxygen species (ROS), and endothelial adhesion
molecules contribute ultimately to leukocytic and lymphocytic infiltration and tissue death
[200-202]. In the case of toxic damage, foreign substances in the blood cause similar tissue
death as in the case of ischemia [203]. In both instances, the hypoxic activation of
endothelium, epithelium and resident leukocytes, in addition to the growing presence of
dead and dying tissue further intensify the pro-inflammatory state, causing continued
release of ROS, transmigration of neutrophils, cytokine release, extravasation, edema, and
irreversible tissue damage [2041. Figure 3.1.1 summarizes the pathophysiology of AKI.
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Figure 3.1.1 - Pathophysiological hallmarks of AKI.
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Inflammation is thought to be at the root of the devastating mortality and resistance to
treatment among patients with AKI [200, 205, 206]. The onset of AKI is not necessarily
immune-mediated, but as soon as the kidney is damaged due to ischemia or toxic injury,
inflammatory processes greatly exacerbate the insult to the organ. Ultimately, it is this
inflammatory insult that causes irreversible damage to occur, greatly impairing the natural
functions of the kidneys, and greatly increasing the probability of death. Novel approaches,
therefore, are currently under development that aim to attenuate the inflammation
underlying AKI. These approaches have thus far shown more promise than former
treatment modalities involving replacement of primary renal function.
3.1.2. Current Extracorporeal Treatment Options and Trials in Cell-
Based Renal Support Devices
For patients undergoing AKI, there are standard treatment options available depending on
the pathophysiology and severity of the disease [207]. In general, patients undergoing AKI
are too hemodynamically unstable to undergo organ transplantation or surgery, and
standard care is directed at supplementing or replacing lost renal function in order to
reestablish homeostasis. The most common supplemental treatment involves
administration of fluids to restore volume and vascular tone. To partially replace the
function that is lost, renal support therapies (RST) are available. Typical RST treatment
involves either intermittent hemodialysis (IHD) or continuous veno-venous hemodialysis
(CWH) [208-211].
New concepts in RST have recently been explored that more completely recapitulate the
function of the kidneys to provide dynamic biologic support that is impossible to achieve
using passive dialysis [212, 213]. To date, the renal assist device (RAD), developed by
David Humes and others at the University of Michigan, has been the most widely tested,
and is the only experimental active RST device that has been tried in the clinic [214-221].
The RAD consists of primary human tubular epithelial cells seeded and grown in the
intraluminal space of standard polysulfone dialyzers. The device is then connected to a
standard dialysis circuit, and patients are treated with CWH in series with RAD. Early
studies by Humes and Mackay demonstrate the capacity of the epithelial cells in their RAD
to actively reabsorb fluid, bicarbonate and glucose; secrete PAH; transport and degrade
glutathione; generate ammonia; and activate vitamin D [214, 220]. Further validation studies
demonstrated the effectiveness of the device to: (1) support and reverse uremia in dogs
[214, 218]; (2) treat 10 patients in the ICU undergoing AKI along with other inflammatory co-
morbidities with a survival rate of 60% (compared to 85% expected mortality) [219]; and (3)
improve survival from 39% in the control passive CWH group to 67% in the group of
patients treated with CWH plus RAD [221]. Unfortunately, the use of the RAD was
terminated during the Phase IIB trial because no demonstrable survival benefit was
observed in larger patient cohorts using the RAD compared to a control device. There was
instead a considerable increase in the risk to patients undergoing RAD therapy.
3.1.3. Clinical and Experimental Testing of Immunomodulation Therapy
in AKI
It is postulated that the failure of the RAD was due in part to inadequate attenuation of the
severe inflammation that is at the root of AKI. New studies increasingly stress the
importance of inflammation in AKI, and emphasize the necessity of anti-inflammatory
therapies to reverse AKI [222, 223]. In an extreme case of AKI in the presence of paraquat
poisoning (serum creatinine of 11.9 mg/dL), researchers reported the reversal of AKI with
repeated methylprednisolone pulse therapy and prolonged dexamethasone treatment
[224]. Several studies have been conducted to evaluate anti-inflammatory treatment for
patients undergoing sepsis, and sepsis-induced multiple organ failure (MOF), including AKI.
A number of investigators have evaluated the effectiveness of cytokine antagonists, such
as recombinant human interleukin (IL)-1 receptor antagonist (IL-1ra) [225-227], TNF-
receptor blockers, or soluble TNF receptors [228]-[229] in patients undergoing sepsis.
Although no survival benefit in sepsis was observed, stratification of the trials showed a
significant reduction in the cases of shock, which typically precipitates AKI. In a study from
2004, it was shown that the inflammatory profile of patients undergoing AKI could be used
54
as a predictor of mortality [222]. Specifically, the serum levels of pro-inflammatory
molecules IL-1 P, IL-6, IL-8, c-reactive protein, and TNF-a were measured, in addition to the
anti-inflammatory marker IL-1 0. During AKI, all cytokines were found to be at a higher level
than baseline. Specifically, it was found IL-6 and IL-8 levels were significantly higher in non-
survivors and the relative levels of these two cytokines could be used to predict mortality.
Interestingly, IL-10 was also found to be significantly elevated in the group of non-survivors,
suggesting a complicated inflammatory state that is neither purely pro- nor anti-
inflammatory. These human studies suggest the need for a therapy for AKI and septic
shock that is dynamic in its response to the inflammatory state of the patient, providing for
immune-regulation more so than promotion or inhibition of inflammation.
Animal studies of AKI have revealed the critical role of various aspects of inflammation in
the pathogenesis of the syndrome, further suggesting a complex inflammatory state as the
underlying cause of high mortality in patients with AKI. In mice deficient of caspase-1, the
protease responsible for cleaving precursors of IL-1 P and IL-1 8, the damaging effects of
AKI were significantly diminished as measured by a decrease in BUN, serum creatinine,
and morphological tubular necrosis score. These findings suggest a significant contribution
to AKI pathophysiology by the pro-inflammatory cytokines IL-1 P and IL-18 [230, 231]. While
it has been shown that knocking out IL-1 alone does not provide for sufficient
renoprotection in the presence of AKI, inhibition of IL-1 P and IL-1 8 together could lead to
attenuation and potential resolution, suggesting the role of a multi-factorial inflammatory
state, and not single inflammatory cytokines as the underlying basis of AKI
pathophysiology [232, 233]. Further evidence of such a multi-factorial state was uncovered
in studies involving the contributions of endothelial adhesion molecules during ischemic
AKI. Kelly et al. demonstrated the effectiveness of a monoclonal antibody (mAb) directed
against ICAM-1, a ligand that binds to the P2 integrins CD1 1 a/CD1 8 and CD1 1 b/CD1 8
expressed on the surface of leukocytes, to reduce the damage caused by ischemic AKI in
rats [234]. A follow-up study by Linas et al. confirmed the adhesion of leukocytes,
specifically neutrophils, via the ICAM-1 ligand in an isolated perfusion model of ischemic
AKI in rat [235]. Another study by Kelly et al. showed renoprotection during ischemic AKI in
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both ICAM-1 knockout mice, and in mice depleted of neutrophils [236]. Their study yielded
no additional benefit to neutrophil-depleted mice administered ICAM-1 mAb, suggesting
the specific role of ICAM-1 in the adhesion of neutrophils during ischemic AKI. More recent
work has begun to uncover the role of T-cells in the progression of ischemic AKI. In a
knockout model of CD4/CD8 in mice, the inhibited T-cell function was implicated to
contribute to attenuated organ dysfunction in ischemic AKI [237]. T-cell deficient mice
(nu/nu) were also found to be protected from injury during ischemic AKI [238]. In this study,
CD4 T-cells, CD8 T-cells, and a combination were administered to the knockout mice, and
only those groups with reconstituted CD4 T-cells showed renoprotection, suggesting a
pivotal role of CD4+ T-cells in ischemia-mediated renal injury.
Taken together, these animal and human studies provide compelling evidence of a
complex inflammatory state underlying the pathogenesis of AKI. In order to effectively treat
the disease, future therapies will need to address this complex state, and provide for multi-
factorial dynamic support.
3.1.4. Attenuating Inflammation During AKI with Marrow-Derived
Mesenchymal Stem Cells
Circulating cytokines present during inflammation often causes the bone marrow to
mobilize cells to track inflammatory signals and provide immunological support [239, 240].
In general, the cells that are mobilized are pro-inflammatory by nature, and mediate the
resolution of infection or damaged tissue by combating pathogens and clearing dead
tissue. Only certain cells that are mobilized are capable of attenuating excessive
inflammation and promoting tissue repair [241, 242]. In the pathogenesis of inflammatory
diseases such as AKI, it has been suggested that a deficit of regulatory cells precipitates an
inappropriate immune response to the initial insult [243].
Bone marrow-derived mesenchymal stem cells (MSCs) and their stromal progeny are
implicated in the regulatory pathway of injury resolution as they possess the capacity to
modulate inflammation and initiate tissue repair programs [41, 244]. Initial studies
investigated the role of the bone marrow in the resolution of AKI [110, 243, 245-248], with
more recent studies focusing specifically on the role of MSCs. In 2004, Morigi et al. were
the first to demonstrate that among the cells from the bone marrow contributing to repair of
the kidneys following cisplatin administration, it was the MSC fraction that was solely
responsible for resolving AKI [186]. They went on to assert the MSCs were likely providing
regenerative support to the kidney in the form of differentiation into renal tubule epithelium,
as evidenced by the detection of Y-chromosome MSCs localized in the renal tubule
epithelium of female mice. In 2005, Togel et al. presented evidence of an anti-inflammatory
contribution that the MSCs were making to aid in the reversal of AKI [104]. They measured
the amount of inflammation afflicting the kidneys during ischemic AKI, and found in mice
administered MSCs, gene expression of IL-1p, TNF-a, and IFN-y was down-regulated
compared to mice administered a saline control. Semedo et al. in 2007 confirmed this work
with another analysis of the attenuation of inflammation with MSCs administered in rats
undergoing AKI [249]. T6gel et al. followed-up their 2005 study with a mechanistic
exploration into the role of paracrine factors in the resolution of AKI [105]. They found the
MSCs secrete renotropic and vasculotropic factors that aid in the repair and regeneration
of the endothelium. More recently, Morigi et al. provided the first evidence that human
MSCs were capable of providing the same renotropic and renoprotective support to a
cisplatinum model of AKI in mice [112].
Controversy exists concerning the primary role of MSCs in resolving AKI. Proponents of the
stem cell hypothesis assert that MSCs are capable of differentiating into cells that aid in the
repair of the kidney, specifically endothelial cells and tubular epithelial cells [186]. Recent
evidence suggests, however, that the MSCs do not differentiate into endothelium or
epithelium in the context of kidney damage, and hence their renoprotective role derives
from another mechanism [151, 250, 251].
3.1.5. Summary
The onslaught of uncontrolled inflammation during AKI is thought to be at the heart of the
high mortality of the disease. Novel therapies are being proposed that attenuate the
inflammation, and provide for organ recovery and tissue repair. Recent work in the realm of
MSC-based therapies has indicated a promising role that these cells might play in
modulating the inflammation during AKI, providing renoprotection to significantly increase
survival. Through paracrine mechanisms, MSCs provide tropic support that is particularly
potent in the kidneys. Administration of these paracrine factors, therefore, may provide for
a novel therapeutic modality that has yet to be fully explored.
3.2. Secreted Factors from Mesenchymal Stem Cells Upregulate
IL-1 0 and Reverse Acute Kidney Injury in Rats
3.2.1. Abstract
Acute kidney injury is a devastating syndrome that afflicts over 2,000,000 people in the US
per year, with an associated mortality of greater than 70% in severe cases requiring
dialysis. AKI represents a significant unmet medical need because the standard-of-care
treatments are not sufficient for modifying the course of disease; gold-standard therapies
are palliative at best. Many groups have explored the use of mesenchymal stem cells
(MSCs) for the treatment of AKI because MSCs have been shown to possess unique anti-
inflammatory, cytoprotective and regenerative properties in vitro and in vivo. Thus far, it is
yet unresolved whether the primary mechanisms controlling MSC therapy in AKI depend
on direct cell transplantation, or whether MSC secreted factors alone are sufficient for
resolving the disease. Here we show that MSC secreted factors, independent of cell
transplantation, are capable of providing a survival benefit to rats undergoing cisplatin-
induced AKI. We observed that when MSC conditioned medium (MSC-CM) is
administered intravenously it protects the architecture of the kidney, prevents tubular
apoptosis and necrosis, and reverses AKI as measured by serum BUN and creatinine. In
addition, we observed that MSC-CM causes IL-10 upregulation in treated animals, and is
important to animal survival. In all, these results demonstrate that MSC secreted factors
are capable of providing support at a level similar to whole cell transplantation, and the IL-
10 increase seen in MSC-CM treated animals correlates with protection of the kidneys and
attenuation of severe AKI.
3.2.2. Introduction
Each year, acute kidney injury (AKI) takes the lives of hundreds of thousands of people
worldwide with a likelihood of death greater than 70% in cases of dialysis dependence
[187, 190]. AKI is an inflammatory organ failure syndrome that is caused by extensive injury
to the kidney parenchyma [252]. There are various etiologies of AKI that stem from pre-
renal, intrinsic renal, or post-renal sources. Regardless of etiology, however, it is thought
that at the root of the devastating mortality is persistent systemic inflammation that
prevents tissue regeneration and disease reversal [223]. Resolution is thought to be
achievable if the inflammatory cytokine storm created by AKI can be attenuated, and
support is provided to aid in the healing of the injured tissue [253]. Unfortunately, the only
existing therapies available to patients with AKI are palliative. Dialysis, while useful to
restore electrolyte balance and remove waste products in the blood, weakly supplements
the failing kidneys without providing anti-inflammatory or regenerative support [189]. Single
molecule therapies directed against AKI have thus far proven insufficient for addressing the
complex pathophysiology underlying the disease [254]. New therapies that can resolve the
disease by addressing multiple aspects of AKI pathophysiology in parallel are desperately
needed.
Mesenchymal stem cells (MSCs) have been explored in pre-clinical and clinical studies as a
potential therapeutic for patients with AKI [255], as MSCs have been shown to possess
potent immunomodulatory and regenerative properties in vitro and in vivo [99, 140]. The
predominant mechanisms of MSC therapy are unclear. Some studies implicate homing,
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engraftment and differentiation as critical for therapeutic benefit [44], and others stress the
importance of secreted factors from MSCs as the key mediators [256]. To attempt to
resolve this issue, we and others have tested MSC secreted factors in various disease
models and compared them to whole cell transplantation. These studies have
demonstrated that MSC secreted factors possess the capacity to provide therapeutic
support to rodents suffering from acute diseases of inflammation (e.g. liver failure, sepsis),
and can provide superior support when compared to cell transplantation [146, 171, 177]. In
particular, we have seen that MSC secreted factors are responsible for a reversal of
proinflammatory cytokine expression and a concomitant increase in the anti-inflammatory
cytokine interleukin-10 (IL-10). To date, it has not yet been definitively resolved whether
this is also the case in AKI. It has been shown in several models of AKI that these factors
are capable of providing significant support [104, 105, 257], as measured by a reduction in
the total injury to the renal tubule epithelium, and preservation of glomerular filtration rate
and creatinine clearance in ischemic and rhabdomyolytic injury models. T6gel and
colleagues demonstrated that when MSCs are transplanted in the context of AKI, very few
cells engraft within hours of transplantation, and no cells can be detected in the kidneys
after 24 hours [104]. Nevertheless, they still observed improvement of the structure and
function of kidneys during ischemic AKI. In addition, they observed a similar reversal of the
proinflammatory injurious state during AKI as we have seen in other inflammatory disease
models with MSC secreted factors, as evidenced by suppression of proinflammatory
cytokine expression and upregulation of the expression of anti-inflammatory mediators in
the kidney at the level of mRNA, including IL-1 0.
In the current report, we demonstrate that MSC secreted factors are capable of protecting
rats from developing severe AKI after cisplatin treatment, and can provide a survival benefit
without cell transplantation. Compared to vehicle and a mock cell control, we saw a
statistically significant survival benefit conferred by MSC conditioned medium (CM),
together with a restoration of both histological and serum kidney function parameters. In
addition, we observed a significant increase in serum IL-10 levels in animals treated with
MSC-CM, and when IL-1 0 was neutralized using an antibody, the effects of the MSC-CM
were partially abated. The results of this study clearly indicate that in AKI, the secreted
factors alone are sufficient for reversal of disease and prolonged survival.
3.2.3. Materials and Methods
3.2.3.1. Statistics
Unless otherwise noted, all experiments were repeated in quadruplicate, and all data were
assessed for significance using a paired, two-tail Student's T test.
3.2.3.2. Cell Culture and Conditioned Medium
MSCs were isolated, purified, grown and characterized, and fibroblasts grown as described
previously [41, 258]. All MSCs were used at passage 2-5. The conditioned medium was
also collected and concentrated as described previously [42]. By convention, 1X refers to
the concentration of conditioned medium achieved when 15 mL of conditioning medium
was incubated in the presence of 2x1 06 cells for 24 hours, collected, and concentrated to a
final volume of 1 mL. This preparation was used for both MSCs and fibroblasts for the
purposes of these studies.
3.2.3.3. Rat Model of Cisplatin-Induced Acute Kidney Injury and MSC-CM
Treatment
All animal studies were performed in accordance with the animal rights policies of the
Massachusetts General Hospital Subcommittee on Research Animal Care. Male SAS-SD
rats (Charles River Laboratories, Wilmington, MA) weighing 275-300g were given cisplatin
(7.5 mg/kg; Sigma, St. Louis, MO) dissolved in physiological saline via i.p. injection to
induce AKI. At various time points after injection, MSC-CM, FB-CM, physiological saline or
mixtures of MSC-CM plus anti-rat IL-1OAb (BD, Franklin Lakes, NJ; Invitrogen, Carlsbad,
CA) were administered intravenously as treatments for the cisplatin-induced AKI. All MSC-
CM and FB-CM doses consisted of 1 mL of 1X CM per dose, and in all cases, the
concentration of IL-1 OAb in each dose was 4 [tg diluted in 1 mL of conditioned medium.
3.2.3.4. Tissue Histology and Staining
Rats were anesthetized with isofluorane (Hospira, Lake Forest, IL) and laparotomy was
performed to access the abdominal cavity. Euthanasia was performed by severing the
abdominal aorta and puncturing the diaphragm. Both kidneys were excised and rinsed
with physiological saline before fixation in buffered formaldehyde (Sigma, St. Louis, MO) for
one week at room temperature. The kidneys were then embedded in paraffin wax and
sliced in 4 pm sections using a microtome. The sections were then analyzed by either (1)
staining with hematoxylin and eosin; (2) TUNEL according to the manufacturer's
instructions (R&D Systems, Minneapolis, MN); or (3) probed with PCNA antibody as
described previously [259]. For the PCNA staining, we used an anti-PCNA clone PC10
(Sigma, St. Louis, MO), followed by a secondary sheep anti-mouse (1:50; Chemicon,
Temecula, CA), and signal development using the Vectastain ABC kit (Vector Labs,
Burlingame, CA). To determine the number of PCNA positive cells per field, representative
images were taken of the kidney samples, 25 images of the medulla and 25 images of the
cortex, and the numbers of positive cells per field were counted and tabulated.
3.2.3.5. Blood Urea Nitrogen (BUN) and Creatinine Measurement
All BUN and creatinine measurements were conducted with whole blood drawn from the
rats and analyzed on a Renal Function Panel according to manufacturer's instructions
(Abaxis, Union City, CA).
3.2.3.6. ELISAs
The ELISA kits used were provided by commercial vendors and were used according to
the manufacturers' instructions (OptElA ELISA sets; BD, Franklin Lakes, NJ).
3.2.4. Results
3.2.4.1. MSC-CM Attenuates Cisplatin-Induced AKI in Rat
In these studies, we chose to use a cisplatin model of AKI in rats. Cisplatin is used
routinely in the clinic as a cancer chemotherapeutic agent, and remains the standard of
care for many malignancies, including ovarian and cervical cancer, because of its strong
therapeutic track record [260, 261]. However, one of the most common and dangerous
complications of cisplatin administration is nephrotoxicity [262], which can lead to death
associated with AKI. The primary hypothesis to be tested was whether MSC secreted
factors, when used to treat lethal cisplatin administration, could provide the multifactorial
support required to protect the kidneys and prevent death by organ failure.
We began our studies by optimizing the cisplatin dose required to induce 75% mortality by
two weeks, and arrived upon 7.5 mg/kg i.p. [263]. We then sought to determine an
effective regimen for treating AKI with MSC-CM. Previous studies illustrating the kinetics of
disease onset demonstrated irreversible damage within the first 72 hours after cisplatin
administration [264]. Hence, we chose five timepoints for i.v. administration of MSC-CM: 3,
9, 24, 48 and 72 hours after cisplatin was given. This regimen provided a significant
survival benefit (Figure 3.2.1); compared to controls, MSC-CM improved survival by
approximately 300% (p < 0.05) [41]. In addition to providing a survival benefit, MSC-CM
also significantly attenuated the severity of cisplatin AKI. When animals were administered
the same lethal dose of cisplatin, BUN and creatinine rose dramatically in vehicle treated
rats by day 3, and continued to climb by day five, indicative of the severity of disease and
irreversibility of the injury (Figure 3.2.2a and 3.2.2b). However, when the animals were
treated with MSC-CM as described above, neither BUN nor creatinine rose dramatically at
any point during the first five days after cisplatin administration. This would indicate that
MSC-CM prevented extensive injury of the kidneys and preserved enough of the
architecture and function of the kidneys such that clearance of BUN and creatinine was not
irreversibly affected.
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Figure 3.2.2 - MSC-CM prevents onset of
severe AKI. Blood was collected from rats
subjected to lethal cisplatin (7.5 mg/kg) i.p.
via tail snip 1, 3 and 5 days following cisplatin
administration. The rats were treated at 3, 9,
24, 48 and 72 hours following cisplatin
administration, with 1 mL of either
physiological saline (n=4), or MSC
conditioned medium (n=3) i.v. (a) BUN and
(b) creatinine were measured to monitor the
extent of renal injury as a function of time
after cisplatin. *p < 0.01 by Student's T-test.
3.2.4.2. MSC-CM Protects the Kidney from Cisplatin-Induced
Nephrotoxicity
From the results of the renal function markers, BUN and creatinine, it seemed likely that the
MSC-CM treatment was protecting the architecture of the kidney, thereby preserving a
normal clearance rate. When the rats were subjected to a lethal dose of cisplatin and then
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Figure 3.2.1 - MSC-CM confers a significant
survival benefit to rats undergoing lethal
cisplatin AKI. At hour 0, cisplatin dissolved in
physiological saline (0.75 mg/mL) was
administered i.p. to male, SAS-SD rats at a
lethal dose (7.5 mg/kg). At hours 3, 9, 24, 48
and 72, 1 mL of either physiological saline
(n=1 2), fibroblast conditioned medium (n=1 0) or
MSC conditioned medium (n=14) were
administered i.v. to the cisplatin-induced AKI
rats. They were monitored for surivival for 30
days. *p < 0.05 for MSC-CM compared to both
FB-CM and saline by Logrank test.
treated with saline, hematoxylin and eosin staining of the kidneys revealed cortical damage
in the form of collapsed Bowman's capsule and proximal tubular necrosis, and medullary
damage in the form of extensive tubular necrosis, deposition of debris and intermediate
tubule casts, all consistent with cisplatin-mediated AKI (Figure 3.2.3). This destruction of
the tubule architecture of the kidney, Bowman's capsule collapse, and obstruction of the
loops of Henle could explain why the BUN and creatinine rose so dramatically by day 5.
The injury was so severe that upon excision, the kidneys were grossly hemorrhagic and the
normal tissue firmness was replaced with a soft and shapeless character. The kidneys of
the rats administered MSC-CM, on the other hand, sustained significantly less injury. H&E
analysis revealed only minor damage in the form of moderate tubular necrosis, loss of
brush borders and denuding of tubular epithelium, but minimally apparent casts or
accumulated debris. On the whole, the kidney was able to retain an non-obstructed
structure, clearly advantageous to maintaining clearance and preserving normal kidney
function even despite toxic injury.
Cortex Medulla
Figure 3.2.3 - MSC-CM protects the
native architecture of the kidney during
() AKI. Hematoxylin and eosin staining of
sections of kidneys from rats administered
a lethal dose of cisplatin (7.5 mg/kg) and
sacrificed at 5 days following cisplatin
administration. The rats were treated at 3,
9, 24, 48 and 72 hours following cisplatin
administration, with 1 mL of either
physiological saline (n=4), or MSC
conditioned medium (n=3) i.v.
We next sought to analyze the type of injury sustained by the kidneys during cisplatin
toxicity. We hypothesized that in addition to frank necrosis induced by cisplatin toxicity,
apoptosis was also present in the kidneys, even as late as 5 days after the cisplatin
injection. We performed TUNEL on these day-5 kidney sections and noted extensive
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apoptotic foci in the medulla of the vehicle treated kidneys (Figure 3.2.4). Periodic
apoptotic cells were observed in the MSC-CM treated kidneys, but 1OX fewer than found in
the vehicle treated kidneys, indicating far fewer apoptotic events. This would suggest that
one mechanism by which the MSC-CM protects the architecture of the kidney is by
preventing apoptosis.
Medulla
Figure 3.2.4 - MSC-CM prevents apoptosis in the loop of Henle.
TUNEL staining was performed on sections of formalin fixed and
paraffin-embedded kidneys from rats administered a lethal dose of
cisplatin (7.5 mg/kg) and sacrificed at 5 days following cisplatin
administration. The rats were treated at 3, 9, 24, 48 and 72 hours
following cisplatin administration, with 1 mL of either physiological
saline (n=4), or MSC conditioned medium (n=3) Lv. Arrows indicate
positively stained nuclei.
We then looked into the prevalence of regeneration in the kidneys to test the hypothesis
that MSC-CM enhances regeneration in the tissue, which contributes to reversal of the
disease and recovery of the animals. We probed for PCNA and found that indeed,
regeneration was far more extensive in the MSC-CM treated kidneys than healthy control
kidneys that only showed scarce dividing cells (less than one per 1OX field on average)
(Figure 3.2.5). Interestingly, PCNA analysis revealed that vehicle-treated kidneys were also
undergoing extensive regeneration. We quantified the number of PCNA positive cells in
each 20X field, and found that the extent of regeneration in vehicle-treated kidneys was
significantly higher than in MSC-CM treated kidneys. As will be discussed below, we
hypothesize this may be a function of the total damage incurred by the kidney, as extensive
damage will require more dividing cells to replenish lost cells compared to moderate or
minimal damage.
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Figure 3.2.5 - Vehicle treated animals require more regeneration to overcome injury to the kidneys during
AKI. PCNA staining was performed on sections of formalin fixed and paraffin-embedded kidneys from rats
administered a lethal dose of cisplatin (7.5 mg/kg) and sacrificed at 5 days following cisplatin administration.
The rats were treated at 3, 9, 24, 48 and 72 hours following cisplatin administration, with 1 mL of either
physiological saline (n=4), or MSC conditioned medium (n=3) i.v.
3.2.4.3. IL-1 0 is Important for MSC-CM Therapy in AKI
Since we saw such a strong response in the rats to MSC-CM in AKI, we next wanted to
begin to explore mechanistic implications of MSC-CM therapy, in particular how MSC-CM
might influence the immune state of the animal during AKI. Our previous work revealed
that during liver failure, the inflammatory state of rats treated with MSC-CM was reversed
compared to vehicle controls [42]: the vehicle treated rats developed high levels of IL-1 P,
TNF-a, IL-6 and IL-1ra, and exhibited low levels of IL-10, while MSC-CM treated rats
developed high levels of IL-10 and lower levels of IL-1P, TNF-a, IL-6 and IL-1ra. In other
models as well, IL-1 0 upregulation has been shown to be a hallmark of MSC therapy [146],
and has been shown to influence the expression of IL-1 P, TNF-a and IL-6 in vitro and in
vivo [104, 265]. In AKI, we therefore hypothesized that MSC-CM was causing enhanced
IL-10 expression in a similar manner. The serum level of IL-10 in MSC-CM treated rats
three days after cisplatin administration was significantly higher than that in vehicle controls
(Figure 3.2.6a). To confirm that the IL-10 we measured did not arise from the MSC-CM
that we injected, we measured via ELISA the amount of IL-10 in MSC-CM. Even though
the MSC-CM was from human cells and the IL-1 0 we measured in the animals was rat, we
nevertheless wanted to confirm there was no cross-reactivity in the ELISA and measured
the MSC-CM independently. We found that the minute positive reactivity of MSC-CM in
the ELISA could not account for the IL-1 0 seen in the serum (Figure 3.2.6b).
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IL-10 was measured via ELISA in whole MSC-CM.
Finally, to test the extent to which IL-10 may be responsible for the therapeutic
effectiveness of the MSC-CM treatment in AKI, we tested the same survival model of
cisplatin AKI (7.5 mg/kg) with MSC-CM coadministered with neutralizing IL-1 0 antibody at
4 [g per dose. Figure 3.2.7 shows the diminished effect of MSC-CM on the survival of
animals when co-administered with neutralizing IL-10 antibody. Compared with the
survival associated with MSC-CM alone, 30% fewer animals survived when IL-1 0 antibody
was present. However, it should be noted that when tested for significance, the p-values of
the differences between MSC-CM vs. MSC-CM with IL-10 antibody were greater than
0.05, suggesting trends rather than significant increases or decreases in survival.
Nonetheless, together these results support the hypothesis that IL-10 is an important
mediator of MSC-CM therapy, and suggest that MSC-CM can stimulate endogenous anti-
inflammatory processes to aid in the reversal of AKI.
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3.2.5. Discussion
We have shown that MSC-CM alone can provide substantial support in AK. Several
studies have shown that transplanted MSCs can provide survival benefit in AKI akin to
what we observed. In one study, iv. administration of human MSCs (2x1 07 cells/kg) in
NOD/SCID mice at 24 hours following lethal cisplatin administration enhanced survival from
0% to 40% [112]. In another, i.p. administration (2x108 cells/kg) was demonstrated to be
sufficient for providing survival benefit to NOD/SCID mice, enhancing survival from 10% to
47% [266]. In our study, we used the secreted factors from the equivalent of 3x1 0y
cells/kg, which is within the same order-of-magnitude as other work demonstrating iv.
administration of MSCs, which is why we might expect a similar result in terms of
protection during AK. Nevertheless, this is not a direct comparison as the MSC-CM
consists of secreted factors from only 24 hours of conditioning, compared to permanent
engraftment of transplanted MSCs and continuous secretion of factors over time from the
engrafted cells [267].
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Figure 3.2.7 - IL-10 antibody abates the
survival benefit of MSC-CM administered to
rats undergoing lethal cisplatin AKI. At hour
0, cisplatin dissolved in physiological saline
(0.75 mg/mL) was administered i.p. to male,
SAS-SD rats at a lethal dose (7.5 mg/kg). At
hours 3, 9, 24, 48 and 72, 1 mL of either
physiological saline (n=12), MSC conditioned
medium (n=14) or MSC conditioned medium
containing 4 Rg/mL neutralizing anti-rat IL-1 0
antibody (n=1 0) were administered i.v. to the
cisplatin AK rats. They were monitored for
surivival for 30 days. *p < 0.05 for MSC-CM
compared to saline by Logrank test.
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Our results are consistent with other studies of MSC-CM in AKI, and show for the first time
that human MSC-CM can provide a survival benefit in the context of AKI. Bi and
colleagues showed that in addition to MSC transplantation conferring a survival benefit to
mice undergoing cisplatin AKI, mouse MSC-CM also provided a 60% increase in survival
[268]. We observed a 300% improvement in survival, which we hypothesize could be
attributed to species differences of the CM [44]. However, since the study of Bi et al. was
executed differently than ours in terms of AKI rodent species, mode of administration of
MSC-CM, treatment regimen and MSC-CM harvesting method, it is difficult to compare the
results of the studies directly. Also, significant reversal of AKI has been reported that
resulted from administration of the ultracentrifuged fraction of MSC-CM in mice undergoing
rhabdomyolytic AKI [257]. The authors present evidence that microvesicles in the
ultracentrifuged fraction provide benefit by horizontal gene transfer that is diminished with
the co-administration of RNAse, as evidenced by histology, BUN/creatinine and electron
microscopy. Nevertheless, the authors did not explore whether the ultracentrifuged
fraction provides a survival benefit, nor do they report whether the whole conditioned
medium can provide a similar or superior benefit. In all, our results here have demonstrated
the best improvement of survival thus far of any MSC study to our knowledge, and show
that the secreted factors alone are sufficient for AKI resolution.
Our previous work has shown that the secreted factors from MSCs, either administered in
the form of conditioned medium (CM) or delivered continuously from an extracorporeal
bioreactor, are capable of providing survival benefit to animals undergoing fulminant
hepatic failure [41, 42]. We observed reversal of the pro-inflammatory cytokine profile in
these animals, with a marked increase in the anti-inflammatory cytokine IL-10. IL-10 has
been implicated in MSC therapy previously in sepsis [146], and has been cited as one of
the more influential factors upregulated during MSC-mediated T-cell suppression [99, 269].
In sepsis, MSCs were shown to upregulate IL-10 in macrophages via prostaglandin E2-
mediated reprogramming. Others groups have shown that certain factors secreted by
MSCs can directly lead to IL-1 0 production [256], including TGF-p [270] and IL-6 [271], two
proteins that are highly expressed by MSCs [172, 272]. IL-10 has also been shown to be
effective as a therapeutic when exogenously delivered to rodents undergoing AKI [273],
confirming the important role that IL-10 can play in reversing the disease. It comes as no
surprise, therefore, that we observed upregulation of IL-10, and blocking the cytokine
caused a decrease in the survival of animals treated with MSC-CM.
In an effort to leverage what we have learned about MSC-CM and begin to translate it to
clinical use, we have recently been working to scale up the extracorporeal bioreactor we
developed to treat fulminant hepatic failure in rodents [41] to accommodate human use
during dialysis for AKI [274]. In our studies of hepatic failure, we discovered that
continuous delivery of MSC secreted factors from a bioreactor can provide a superior
therapeutic benefit compared to bolus administration of MSC-CM [41]. Hence, we
developed a platform that will integrate with existing dialysis circuits to allow for delivery of
MSC secreted factors directly into the bloodstream of patients with AKI undergoing
dialysis. When seeded in the bioreactor, we showed the MSCs are capable of remaining
viable and functional while retaining their undifferentiated phenotype under flow conditions
mimetic of clinical operation [274], which suggests that scale-up of the prototype device
from our liver failure studies will likely result in a similarly active device for clinical use. The
results we report here further support the hypothesis that the secreted factors from MSCs
delivered into the bloodstream of animals suffering from AKI can fundamentally change the
outcome of those suffering from the disease, and provide reasonable evidence that the
MSC bioreactor platform could be effective in treating human AKI.
One unexpected result was the significantly enhanced regeneration in vehicle-treated
kidneys compared to MSC-CM-treated. This is contrary to earlier findings that MSCs
promote regeneration in kidneys during AKI [112], as clearly evidenced by PCNA staining.
This is also in contrast to studies we have previously performed that suggested MSC-CM
promotes regeneration in the context of fulminant hepatic failure in rat [42]. In these latter
studies, there was clearly enhanced regeneration in the livers of rats treated with MSC-CM
compared to vehicle controls. In both cases, however, the time at which the animals are
sacrificed and analyzed is important to consider. In our liver failure studies, the rats were
sacrificed and tissue extracted for analysis only 48 hours after the final dose of D-
galactosamine, the agent used to induce FHF, and in the AKI study, the mice were
sacrificed four days after cisplatin. In the current study, the animals were sacrificed 48
hours after the final dose of MSC-CM, which is five days after the induction of AKI with
cisplatin. Therefore, it is possible that had the animals been sacrificed earlier in these
studies, we might also observe a higher rate of regeneration. T6gel et al. observed that
PCNA staining is significantly higher in kidneys from rats treated with MSCs 24 hours after
reflow during ischemia-reperfusion AKI [104]. It is also possible that the higher rate
observed in the vehicle-treated kidneys is a consequence of the prevalent damage to those
kidneys that is not suffered to the same extent in those treated with MSC-CM. Finally,
since PCNA staining may not be specific to proliferating cells per se and could also be
indicative of DNA repair, which would be required extensively in the context of cisplatin
AKI, it is possible that discrepancies in PCNA staining between the MSC-CM treated and
saline treated animals could be suggestive of differences of the two therapeutic
approaches in terms of DNA damage. In any case, it is clear from the physiological
response of the animals to MSC-CM that the regeneration and/or repair that is taking place
by day 5 is sufficient to restore function to their kidneys to normal levels.
In conclusion, we have demonstrated that MSC secreted factors, independent of cell
transplantation, are capable of stimulating endogenous anti-inflammatory programs via IL-
10, leading to a significant survival benefit to rats undergoing cisplatin AKI. These results
suggest that the primary mechanism of MSC therapy is based on the secreted factors of
the cells, which should aid in the optimization of proper therapeutic protocols for treatment
of AKI patients with MSCs. It also suggests that altemative approaches to transplantation
might also prove successful for administering MSC therapy, including administration of the
conditioned medium as a direct injectable, or continuous delivery of these secreted factors
from bioreactors into the bloodstream of AKI patients, thereby circumventing potential risks
associated with transplantation [151, 152]. In all, these results present a promising and
innovative new approach to treating this deadly disease that leverages the natural strengths
of the MSC secretome.
3.3. Phenotypic and Functional Characterization of Human Bone
Marrow Mesenchymal Stem Cells in Hollow Fiber Bioreactors
3.3.1. Abstract
The transplantation of human mesenchymal stem cells (MSCs) is a novel
immunotherapeutic approach that is currently being explored in many clinical settings.
Evidence suggests that the efficacy of cell transplantation is directly associated with
soluble factors released by human MSCs. In order to harness these secreted factors, we
integrated MSCs into large-scale hollow-fiber bioreactor devices in which the cells
(separated by a semipermeable polyethersulfone (PES) membrane) can directly and
continuously release therapeutic factors into the blood stream. MSCs were found to be
rapidly adherent and exhibited long-term viability on PES fibers. The cells also preserved
their immunophenotype under physiologic fluid flow rates in the bioreactor, and exhibited
no signs of differentiation during device operation, but still retained the capacity to
differentiate into osteoblastic lineages. MSC devices released growth factors and cytokines
at comparable levels on a per cell basis to conventional cell culture platforms. Finally, we
utilized a potency assay to demonstrate the therapeutic potential of the collected secreted
factors from the MSC devices. In summary, we have shown that culturing MSCs in a large-
scale hollow fiber bioreactor is feasible without deleterious effects on phenotype, thus
providing a platform for collecting and delivering the paracrine secretions of these cells.
3.3.2. Introduction
Mesenchymal stem cells (MSCs) are a subpopulation of adherent bone marrow cells that
have a long-standing period of clinical testing in a number of disease states ranging from
osteogenesis imperfecta to graft-versus-host disease [9, 35, 36, 128, 275]. Their
therapeutic use has expanded in recent years after it was observed that MSC transplants
could modulate the immune response to tissue injury [119, 120]. The primary method of
administration has been the intravenous transplantation of these cells. However, the
viability of MSCs after intravenous transplantation exponentially declines [14, 15] limiting
the therapeutic window of treatment. Also, the possibility of unwarranted side-effects of
transplants, such as maldifferentiation or systemic reduction of immunosurveillance [151,
152, 158, 159], remains to be determined in ongoing longitudinal patient trials.
A corresponding line of research has emerged to define the mechanism of action of MSC
transplants. Many studies have demonstrated that secreted factors released by MSCs
during transplantation alter the function of neighboring cells, which can result in a tissue-
sparing, anti-inflammatory outcome (reviewed in [267]). These secreted factors can be
broadly classified by whether they are basally produced, inducible, or the products of
metabolic conversion of local substrates. For example, MSCs naturally secrete IL-1 ra and
VEGF [276, 277], can be induced by toll-like receptor activation to secrete prostaglandin E2
and sTNFR1 [146, 278], or can catabolize tryptophan into a T cell suppressant, kynurenine,
by the action of indoleamine 2,3-dioxygenase [176, 279]. These reports solidify the
concept of MSCs being a dynamic reservoir of soluble factors that require suitable
methods to deliver this molecular therapy in a controlled manner.
Some investigators have evaluated the use of MSC secretions by administering MSC
conditioned medium (MSC-CM) by various routes. Initial work demonstrated that local
injections of MSC-CM could supplant the effect of a MSC transplant in protecting cardiac
muscle viability and function in ischemic hearts during acute phases of recovery [280, 281].
Our group demonstrated that systemic delivery of MSC-CM by means of an intravenous
bolus led to an improvement in short-term survival of rats undergoing organ failure [41]. We
also designed prototype flat-plate bioreactors to create a single platform for MSCs to
secrete factors continuously into the bloodstream. These extracorporeal support devices
showed improved survival in therapeutic trials in rodents [41, 177]. Collectively, these
studies indicate that MSCs can be integrated into blood-contacting devices and can elicit
therapeutic effects by paracrine action alone.
On this basis, we evaluated human scale hollow fiber bioreactors as a means to harvest
and/or deliver MSC secreted factors in a clinically-relevant continuous blood flow device.
These devices differ from our lab-scale prototype in that MSCs are seeded onto 3D hollow
fibers and are separated from continuous fluid flow by a porous hollow fiber membrane. In
this report, we have demonstrated that MSCs retain their phenotype in hollow fiber
bioreactors and their secretions maintain bioactivity during their culture time in devices.
3.3.3. Materials and Methods
3.3.3.1. Mesenchymal Stem Cell Isolation
Primary human MSCs were derived from whole human bone marrow aspirates (Lonza,
Basel, Switzerland). Bone marrow was firstly diluted in a 1:1 ratio with sterile phosphate
buffered saline (PBS). The diluted marrow was subsequently added on top of an equivalent
volume of Ficoll-PaqueTM PREMIUM (GE Healthcare, Uppsala, Sweden); this was then
spun at 1500 RPM for 30 minutes. Centrifugation separated the mixture into four density
partitions: serum/PBS, buffy coat, Ficoll, and hematocrit. The top layer of serum/PBS was
first carefully aspirated as to not disrupt the buffy coat layer. Once enough volume was
removed, the buffy coat was transferred to another tube. An equal amount of medium
(recipe in 2.2. Cell culture) was added and the mixture spun at 1500 RPM for 5 minutes.
The supematant was removed and replaced with 25 mLs of culture medium and the total
number of cells was determined using hemocytometer. Cells were then diluted to a plating
density of approximately 10,000 cells/cm2 in T175 (Coming) flasks in a 370C, 10% CO2
incubator. Adherent cells were allowed to grow for one week before the medium was
changed and non-adherent cells removed. Cells were then cultured for another week after
which the medium was changed every three days. Once at a confluency of 70-80%, cells
were frozen down in culture media containing 10% DMSO (v/v) and individual lots from this
master cell bank were used for experimentation.
3.3.3.2. Cell culture
MSCs were used between passages 1-5 and grown in medium composed of: alpha-
modified Minimum Essential Medium Eagle (Sigma, St. Louis, MO), 20 mg/L gentamycin
(Sigma), 15% FBS (Hyclone, Logan, Utah), 1 ug/L rhFGF-basic (R&D Systems,
Minneapolis, MN), 100 U/ml penicillin (Sigma), and 100 [tg/ml streptomycin (Sigma) and
titrated to a pH of 7.4. Cells were grown at 370C in T1 75 culture flasks in a 10% C2,
humidified incubator. Medium was replaced every three days and cells were replated at a
split ratio between 1:2 and 1:10 using 0.25% trypsin-EDTA after they reached 80-90%
confluency.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole human blood in the
same manner as MSCs, described above, using a Ficoll-PaqueTM separation technique.
PBMC culture medium was composed of: RPMI 1640 (Sigma), 10% heat inactivated FBS
(Hyclone), 50 U/ml penicillin (Sigma), and 50 stg/ml streptomycin (Sigma) and titrated to pH
7.4. Cells were grown at 370C in a 5% C02, humidified incubator.
3.3.3.3. Hollow fiber bioreactor seeding and operation
Hollow fiber dialyzers were generously donated by NxStage (Lawrence, MA). The encased
ultrafiltrate hollow fibers were constructed from polyethersulfone (PES) and spanned a total
surface area of 1.6 M2. Each fiber had a lumen diameter of 200 [tm. For initial cell seeding
experiments, the bioreactor was disassembled and individual hollow fibers were sterilely
organized into a bundle of approximately 25 fibers and placed in 6 cm tissue culture dishes
for incubation with a cell suspension. Approximately 3.0 x 105 cells in a volume of 200 [.L of
culture medium were applied onto each 1x1 cm fiber bundle and allotted a period of three
hours for attachment in an incubator. After which, 6 mLs of medium was added and the
cells were allowed to grow on the fibers for the duration of the experiment. This method of
seeding ensured that the vast majority of the cells were attaching to the fibers and not the
plate since the cell suspension volume was just sufficient enough to wet the fibers and not
seep onto the plate.
In preparation for cell seeding in the assembled device, the intra/extracapillary spaces were
manually flushed with 300 mLs of sterile PBS. Excess fluid was removed by aspiration. The
intracapillary space was then filled with culture medium and was considered full when
medium was seen exiting the other port on the device. Cells were taken from frozen stocks,
thawed, centrifuged, and resuspended in a volume of approximately 50 mLs of fresh
culture medium and counted. The cell suspension was syringe injected into the
extracapillary space through one dialysate port. Extra medium was added until the entire
extracapillary space was filled as assessed by medium evacuation from the opposite port.
The device was then placed in an incubator overnight to allow for the adherence of cells to
the fibers. The following day, the extracapillary space was manually flushed with 200 mLs
of PBS to remove any non-adherent or dead cells and the volume again replaced with
culture medium. The device was then attached to the closed loop perfusion system
consisting of a medium reservoir and peristaltic pump (pump drive - Masterflex [/S; pump
head - Masterflex easy-load 3; Cole-Parmer Instrument Co., Vernon Hills, IL) and then
placed back in the incubator, and allowed to run for the duration of the experiment.
Intracapillary flow rate was set to 200 m~lmin with a resulting extracapillary flow rate of 10
mL/min.
3.3.3.4. Fluorescent and Scanning Electron Microscopy
To assess the ability of cells to grow on hollow fibers in a static environment, live cell
imaging was performed as per the vendor provided protocol for the LIVE/DEAD
Viability/Cytotoxicity Kit (Invitrogen/Molecular Probes, Carlsbad, CA). Approximately, 3x105
cells were allowed to adhere to fiber samples overnight in standard culture medium prior to
staining and fluorescent imaging. The morphology of PES hollow fiber and adhered MSCs
were characterized under scanning electron microscope (Ultra55, Zeiss). MSCs growing on
the fibers were fixed with 2.5% glutaraldehyde and then serially dehydrated in increasing
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concentrations of ethanol solution; 20, 50, 70, 90, 95 and 100%. Before imaging, the
samples were sputter-coated with Au target for 2 min in 20mA (HAR-024, Cressington).
3.3.3.5. Osteoinduction analysis
MSCs were trypsin-extracted from the device after a 48-hour perfusion and analyzed for
signs of osteogenic differentiation. The entire bioreactor was cleared of media, flushed with
PBS, and filled with trypsin. Cells were allowed to detach for half an hour with mechanical
agitation applied every 10 minutes. Cells were removed through syringe aspiration. This
aspirate was then added to an equal volume of media, centrifuged, and the number of cells
counted. To test for signs of differentiation, 2x105 cells were firstly plated onto a 2.5 x 7.5
cm glass slide and allowed to adhere overnight. The following day the cells were stained
with Alizarin Red S (Sigma) as per standard protocol and imaged. In a separate set of
experiments we tested their ability to differentiate after device operation. MSCs (5x1 04) cells
were plated in a Lab-Tek Chamber Slide (Nunc, Rochester, NY) cell culture system and
grown in StemPro Osteocyte/Chondrocyte differentiation medium (Gibco/Invitrogen) for a
period of approximately 3 weeks with complete medium changes every 3 days. The cells
were visually assessed for morphological changes, stained with Alizarin Red S, and imaged
once again to verify differentiation.
3.3.3.6. Metabolite analysis
Analysis of two secreted metabolites was used as additional validation of cell viability in the
hollow fiber dialyzer. Measurements of glucose (Stanbio, Boeme, TX) and lactate (Trinity
Biotech, Bray, Ireland) were performed per vendor protocols. Medium samples were taken
over a period of 48 hours from a bioreactor seeded with 200 million cells and perfused with
an extracapillary flow rate of 10 mLfmin; samples were stored at 4*C prior to analysis.
Growth factor and cytokine analysis
To further characterize the seeded MSCs in the hollow fiber dialyzer, measurements of
interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) were used. Medium
samples collected at 24 and 48-hour time points from a bioreactor seeded with 200 x 10'
cells and perfused with extracapillary flow rate of 10 mL/min were stored at 40C prior to
EUSA analysis as per BD OptEIA TM protocol (BD Biosciences, San Jose, CA).
3.3.3.8. Flow cytometry
Following a 48-hour perfusion, cells were removed from the bioreactor using 0.25%
Trypsin-EDTA and analyzed for phenotypical markers to validate preservation of a MSC
phenotype. Cells were stained with BD Pharmigen TM CD44, CD29, CD73, and CD1 1 b
antibodies (BD Biosciences) after which flow cytometry was performed using standard
operating procedures (Cell Lab QuantaTM SC, Beckman Coufter, Brea, CA).
3.3.3.9. Potency assay
Approval for the collection of blood from healthy volunteers was obtained from the
Institutional Review Board of Massachusetts General Hospital. A potency assay ([258]; see
Appendix) was performed in order to validate the influence of MSC secreted factors on
peripheral blood mononuclear cells (PBMCs). Briefly, PBMCs were isolated by Ficoll-
PaqueTM separation from whole human blood. Cells were plated in round bottom 96-well
plates at 1x10Q cells/well cells in 50 tL of complete RPMI medium. 50 IL of MSC growth
medium or MSC-CM from a cell-seeded bioreactor was then added to each well bringing
the volume up to 100 [tL Cells were incubated for 18 hours, after which 50 [iL of 30 [g/mL
lipopolysacharide (LPS) (10 [g/mL final concentration) was added and incubated for 5
hours. The plate was then spun down at 1500 RPM and the supematant removed and
3.3.3.7.
stored at -80*C prior to analysis for IL-1 0 release. IL-1 0 levels were measured by standard
ELISA methods (BD Biosciences).
3.3.4. Results
3.3.4.1. MSCs adhere and retain fibroblastoid morphology on
polyethersulfone hollow fibers
The predominant fiber material used in clinical bioreactors is polyethersulfone (PES). PES
is a standard material used in bioreactors and filtration membranes for numerous reasons
including high thermal and chemical resistances, exceptional biocompatibility, and low
protein binding. We first assessed if human MSCs could adhere to this material without the
use of a cell-permissive coating. Cells were initially seeded in a static environment on fibers
isolated from a hollow-fiber bioreactor. The efficiency of static seeding was approximately
80%. This was determined through viable cell counting and the subtraction of cells found in
suspension from the initial number of cells seeded on a fiber bundle after 24 hours of
incubation (data not shown). Figure 3.3.1a illustrates the initial adherence of viable human
MSCs after 24 hours visualized by calcein AM staining. Throughout the five-day time
course, viable cells began to spread along the circumference of the fiber bundles (Figure
3.3.1b and 3.3.1c). Scanning electron microscopy imaging validated preserved
fibroblastoid morphology with a classical spindle-like shape (Figure 3.3.1d) and transversal
cell attachment (Figure 3.3.1e). MSCs were also found to attach to other similar substrates
such as polysulfone and cellulose that are less often used in bioreactors (data not shown).
Figure 3.3.1 - MSC adhere to polyethersulfone hollow fibers and remain viable after long-term
culture. Fluorescent micrographs of MSC adherence and morphology on PES hollow fibers after (A) 24
hours, (B) 48 hours, and (C) 6 days. Cells were stained with Calcein AM for viability. Scanning electron
microscopic images show (D) MSCs with typical fibroblastoid morphology within the constructs of a (E)
complex three-dimensional environment.
3.3.4.2. MSCs are viable in a hollow fiber bioreactor under flow conditions
There are two distinct compartments within a human-scale hollow fiber bioreactor that
contain different chemical environments. Blood is typically flowed at a velocity of 100-400
m/min through the lumen of the hollow fibers in the device. An ultrafiltrate is driven
through the fiber pores into the extraluminal space in a pressure-dependent manner. The
membrane pores have a molecular weight cut-off of less than 50 kDa and thereby deflect
large macromolecules. We inoculated MSCs into the extraluminal compartment of the
hollow-fiber bioreactor and evaluated their viability under clinical perfusion conditions.
Approximately 200 x 106 human MSCs were seeded by gravity flow into the extraluminal
space and allowed to adhere on the fiber bundles overnight before beginning perfusion.
After cell adhesion to the fibers, these devices were integrated into a fluidic circuit that
enabled serial testing of the device effluents over time (Figure 3.3.2a). To increase the
throughput of experimentation, we also constructed parallel reactor modules with minimal
hardware components (Figure 3.3.2b). A clinically-relevant intraluminal flow rate of 200
mL/min perfused the device for 48 hours with an extraluminal flow rate of 10 mL/min.
Medium was sampled daily from the reservoir and the viability of human MSCs was
assessed through metabolic utilization of medium substrates. Glucose levels decreased
over the 48-hour time course while lactate rose over time. These data quantifying glucose
consumption and concomitant lactate production indicate viable cells that are employing
glycolytic metabolism within the bioreactor (Figure 3.3.2d).
Figure 3.3.2 - MSCs are metabolically active during device operation. (A)
Photograph of multi-device operation in vitro. (B) Schematic of a
recycling flow circuit with an intracapillary flow rate of 200 mUmin. and
extracapillary flow rate of 10 mL/min. MSCs are seeded on the
extraluminal space.
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3.3.4.3. MSCs express an undifferentiated phenotype after exposure to
bioreactor culture
Once we determined that MSCs were indeed viable over time in bioreactor culture, we next
evaluated if their phenotype had changed. We isolated cells by trypsin after two days of
bioreactor culture at the same rates described previously and assessed the
immunophenotype and osteogenic differentiation of human MSCs after device operation
(Figure 3.3.3a). Cells stained positive for CD44 and CD73, but negative for CD1 1 b and
CD45 (Figure 3.3.3b) consistent with an established surface phenotype of human MSCs
[45]. These results suggest human MSCs retain their immunophenotype under flow in a
three-dimensional hollow fiber configuration.
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Figure 3.3.3 - MSCs retain their identity and differentiation potential after bioreactor operation. (A) Glucose
consumption and lactate production over time of perfusion show cells maintain viability throughout a 48-hour
time course in a bioreactor under flow. N=3. (B) Histograms of classical immunomarkers used to identify
MSCs. A phenotype of CD44+, CD45-, CD1 1 b-, CD73+ surface expression is preserved after a 48-hour
bioreactor perfusion. Analysis was performed on a device seeded with 200 x 108 cells exposed to an
ultrafiltrate flow rate of 10 mUmin. Black histogram is a stained sample and grey histogram is isotype control.
N=2 (C) Microscopic images of Alizarin Red staining of MSCs directly after perfusion. Negative staining
confirms that cells taken directly from the device showed no signs of osteogenic differentiation. (D) Alizarin Red
stain of MSCs isolated from the device and differentiated for three weeks in osteoinductive medium
demonstrating MSCs still retain the potential to become an osteoblastic lineage after device operation. N=2.
We also evaluated osteogenic differentiation of MSCs from the bioreactor. Cells
immediately taken from the device showed no osteogenic differentiation as measured by
Alizarin Red staining for mineral content (Figure 3.3.3d). In addition, MSCs isolated from
the device were also tested for their capacity to differentiate after incubation with
osteoinductive factors. After three weeks of culture in osteogenic differentiation medium,
MSCs stained positively for rich calcium deposits verifying the capacity to still produce
osteoblastic progeny (Figure 3.3.3d).
3.3.4.4. Secretion of cytokines and growth factors by human MSCs is
maintained in a hollow fiber configuration
Human MSCs are known to secrete a wide spectrum of molecules that naturally support
hematopoiesis in vivo. We examined two classical, but distinct factors: interleukin (IL)-6 and
vascular endothelial growth factor (VEGF). IL-6 is a pleiotropic cytokine that is essential for
lymphocyte differentiation and antibody production [282]. During initial stages of
inflammation, IL-6 has demonstrable systemic effects on epithelial cell regeneration [2831,
muscle contraction [284], lipolysis [285], and wound repair [286]. IL-6 was secreted by
MSCs accumulated in the reservoir of the bioreactor circuit and was comparable to
secretion in 2D tissue culture plates (Figure 3.3.4a).
VEGF is the quintessential growth factor involved in the stimulation of angiogenesis - the
formation of new microvessels [287]. The release of VEGF by MSCs has been implicated in
the therapeutic response associated with transplantation. VEGF appeared to plateau over
time in the device while continuing to increase in a 2D culture plate (Figure 3.3.4b). These
data suggest that the secretome of human MSCs can be preserved in a bioreactor culture
platform.
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3.3.4.5. The effluent of MSC-laden devices increases the production of
IL-i 0 from PBMCs
Our prior experiments demonstrated that human MSCs retain their viability/identity in
hollow-fiber bioreactors and that bioactive molecules can be isolated from the effluent of
the device. As a proof-of-concept, we lastly explored if human MSC secreted factors
retained potency when considered for therapeutic applications. Human MSC secretions
are reported to have paracrine, anti-inflammatory effects on immune cells. We developed
an in vitro potency assay of human MSC secretions that involves the incubation of
conditioned medium (MSC-CM) with human PBMCs in the presence of LPS as a model,
pro-inflammatory agent (see Appendix for a detailed discussion of this method of potency
assessment). When employed, MSC-CM leads to the upregulation of IL-1 cytokine
release, which is directly associated with the therapetic effect of MSCs in immune-
mediated diseases [146]. We collected medium from the MSC bioreactor and executed our
PBMC potency assay without concentration of MSC-CM. MSC-CM from the device
showed a significant increase in IL-i0 production from LPS-stimulated PBMCs as
compared to 2D controls over time (Figure 3.3.5).
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3.3.5. Discussion
Today, hollow fiber bioreactors provide a useful platform for the production of cell-derived
factors with exploratory application in clinical settings [216, 221, 288, 289]. MSCs, in
particular, provide an ideal cell type to use in bioreactors given the reported therapeutic
potential of their secreted molecules [280, 281]. Furthermore, the fluidic environment in a
hollow fiber bioreactor is a simplified representation of the niche that MSCs are naturally
found within the bone marrow. MSCs are perivascular cells that are accustomed to being
proximal to blood-flowing sinusoids in vivo [68, 74, 75]. To recreate this microenvironment,
we have developed MSC coatings for hollow fibers found in continuous blood flow devices.
Our findings demonstrate that MSCs retain their phenotype after culture in hollow fiber
bioreactors and have enhanced anti-inflammatory secreted factors.
The first aspect of engineering human MSC coatings was to determine if the cells would
adhere to PES fibers. Prior studies have reported that a wide of array of human cells are
capable of growth on the fibers and that surface modifications have improved attachment
for particular cells [290, 291]. We observed that MSCs did not require any surface
modifications to adhere to PES fibers. Although the mechanism by which MSCs adhere to
PES fibers has not been evaluated, we speculate that extracellular matrix proteins found in
the growth medium may serve as a temporary substrate for the cells to then lay down a
more permanent matrix.
The transition from static two-dimensional tissue culture to a dynamic three-dimensional
bioreactor introduces a number of new variables that may affect the phenotype and
functional characteristics of cells. Such changes in substrate composition and shear stress
have been used as tools to guide the differentiation of MSCs [292], although there has been
no work regarding culture in a hollow fiber bioreactor. Our studies have shown that the cells
retain viability for a period of at least 48 hours when placed in perfusion culture. Four
characteristic MSC surface markers (CD44+, CD45-, CD73*, CD1 1 b-) remained expressed
at known levels when exposed to shear while adherent on the fibers. In addition, we
demonstrated that MSCs do not differentiate within the device but retain the capacity to do
so after bioreactor operation.
An essential component of this cell-based technology relies on the ability of MSCs to
secrete soluble factors in a consistent fashion within this new culture platform. There are
clearly numerous soluble factors that could have been chosen from the compendium of
MSC secreted molecules. We chose VEGF and IL-6 as representative molecules from
distinct protein families. Our proteomic analysis indicated secretion of both VEGF and IL-6,
although the trends were distinct. IL-6 exhibited a continual upward trend while VEGF
levels nearly reached a plateau within 24 hours. The dynamics of each secreted species
should therefore be kept in mind if the end-goal of a MSC device is to harvest a particular
molecule en masse.
Beyond the isolation of individual factors from MSCs, we sought to evaluate the therapeutic
potential of the collected factors released by MSCs in this device. We employed a potency
assay that we have developed to measure the anti-inflammatory cytokine release of LPS-
stimulation human PBMCs after incubation with MSC-derived factors. Our study shows
that MSCs continue to secrete factors that upregulate IL-10 production in PMBCs. As
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opposed to the use of conditioned medium from MSCs cultured in conventional tissue
culture flasks, an intermediate medium concentration step was not required before using in
our potency assay which suggests that the unknown, causative agents for IL-10
upregulation are found at target concentrations in the device effluent at the given cell mass
employed. We observed a time-dependent increase in potency, which alludes to the
possibility that factors are accumulating in the circulating medium collection chamber that
was sampled. A more comprehensive evaluation of the MSC secretome in this continuous
flow environment may provide mechanistic insight into active agents that induce an anti-
inflammatory phenotype in PBMCs.
Clinical precedence has been established for the therapeutic use of cellular hollow-fiber
devices in acute liver and kidney injury, whereby epithelial cells have been used in these
extracorporeal devices as an artificial method of organ support [221, 293]. Our therapeutic
approach deviates from these predicate devices by delivering cytoprotective and
immunomodulatory molecules rather than attempting to recapitulate the function of an
injured organ. The results from this study support the use of MSC-based devices for
indications that require an increase in IL-1 0, which include a number of immune-mediated
conditions [294]. This platform can also be viewed as highly adaptable and not merely
limited to IL-10 boosting therapies. For example, MSC secreted factors have also been
shown to suppress TNF-a and IL-1 levels in vivo [42]. Since MSCs are retained outside of
the body using this technology, it may also be possible to titrate therapeutic dosing by
adjusting the cell mass in the device within an estimated maximum greater than one billion
cells. This approach can offer more flexibility than cell transplantation that is limited by
adverse events associated with transplanting too many cells. Ultimately, a MSC-loaded
hollow fiber bioreactor may act as a combinatorial therapeutic delivery system for the
treatment of inflammatory diseases.
4. Deriving Novel Protein Therapeutics Inspired by Bone
Marrow Mesenchymal Stem Cell Secretions
4.1. Introduction
In the last chapter, Chapter 3, we saw that, consistent with previous results from our lab,
MSC-CM possesses the molecular means for conveying significant therapeutic support in
the context of acute kidney injury, a devastating inflammatory organ failure syndrome that
is responsible for hundreds of thousands of deaths annually worldwide. A critical step in
the direction of translation was also taken as we worked to scale-up the MSC bioreactor
platform pioneered by my predecessors [41] to accommodate large animal testing and
eventual human use. It will not be disclosed in much further detail in this thesis, but work is
ongoing in this area, including large animal testing, and will continue as we push towards
commercial development of this technology.
In this chapter, we will diverge from the topics of the previous chapters and embark on a
journey inspired by the observations and discoveries made therein. As described in the
first chapter of this thesis, we first began our investigation into the contents of MSC
secreted factors as an extension of our work in MSC therapy: we were interested in better
understanding the mechanisms of action of MSCs through the characterization of their
secreted factors. Nevertheless, we quickly recognized the potential value of our discovery
from the perspective of protein drug discovery, and instead sought to make best use of this
collection of therapeutic factors as a source of novel candidate therapeutic molecules.
The successes we enjoyed as a result of this departure will -be described in this chapter.
Without question, while we did pursue a divergence from our previous work, it was
convergence of many aspects of the previous work of ours and others that made this new
direction possible. In particular, the development of a biologically relevant potency assay
using primary human peripheral blood mononuclear cells with a measurable, reproducible
and positive output, relevant to human disease: this was one of the critical turning points
that allowed us to venture down this path. We have since used this potency assay
throughout our work (as described in earlier sections and outlined in detail in the Appendix),
but many of the experiments that validated its predictive power in vivo and its
demonstrated reproducibility were performed while pursuing the work described in this
chapter.
Before I describe the results of this work, I would like to first introduce several concepts
and review the current literature to provide some background for the problem we sought to
solve.
4.1.1. Dissecting Conditioned Medium to Identify Mediators of Cellular
Function
The concept of probing the contents of secreted molecules from cells is not new. In fact,
many of the most important cytokine discoveries came out of experiments and
observations not unlike those we describe in the previous chapters. However, the
methodologies employed to dissect secreted contents of cells have changed over the past
decades, and later in this chapter we will go into the details of how we developed a new
approach to probing the contents of cell secretions that leverages contemporary
technologies. Nevertheless, the standard, and widely accepted approach to dissecting a
heterogeneous mixture of molecules involves separation and identification, usually entailing
chromatography followed by mass spectrometry, respectively. Many of the examples of
conditioned medium dissection have leveraged these methods to identify many powerful
molecules involved in a wide variety of cellular processes. Table 4.1.1 highlights just a few
of the many examples of proteins discovered by taking this approach.
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Table 4.1.1 - Cytokines and growth factors discovered in conditioned medium
Protein Type of CM Potency Assay(s) Chromatography Other Separation Uters of CM Ref
GCSF Mouse lung Mouse Salting out N/A 3 [295]
stimulated with myelomonocytic Phenyl-sepharose
LPS leukemic cell Bio-Gel P60(WEHI-3B)
differentiation Phenyl-silica HPLC
TSK gel HPLC
LIF Mouse L929 Mouse myeloid DEAE-cellulose (anion Ammonium-sulfate 93 [296]
fibroblast cells leukemic cell (Ml) exchange) precipitation
differentiation Sephadex G-200
Phenyl-sepharose
C18 Hydrophobic Support
TSK gel HPLC
IL-2 PHA- T-cell proliferation DEAE-cellulose (anion Ammonium-sulfate 1.5 [297]
stimulated as determined by exchange) precipitation
human [aH]thymidine Ultrogel HPLC Dialysis
lymphocytes Isoelectric focusing
PAGE
MCP-1 THP-1 cells Monocyte DEAE-cellulose (anion Dialysis 21 [298]
stimulated with chernotaxis exchange)
LPS, silica and Heparin sepharose
hydroxyurea Sephacryl S-200 gel HPLC
Cation exchange
Reverse phase HPLC
SCF Buffalo rat liver Mouse DEAE-cellulose (anion Dialysis 336 [299]
cells (BRL-3A) hematopoietic exchange) PAGE
stern cell Ultrogel HPLC
proliferation Agglutinin-agarose
cl proen mast S-sepharose (cation exchange)
determined by Reverse phase HPLC
[H]thymidine
Interferon Human Interferon Sephadex G-100 gel filtration Acid precipitation 10 [300,
leukocytes protection of Ucrosorb RP-8 HPLC 301]
stimulated with MBDK bovine
the Newcastle kidney epithelial LicrosOrb diol HPLC
disease virus cells when
challenged with
virus
Biochemistry has taught us that there are properties of all molecules that allow them to be
uniquely singled-out from a heterogeneous mixture. For example, size, charge, polarity
and solubility are properties of all biomolecules that are commonly used for separation.
Common separation strategies take advantage of the fact that very few molecules possess
the exact same combination of chemical and physical properties - while some molecules
exhibit very similar charge and polarity, they might differ significantly in size, etc. The field
of chromatography is dedicated to the development of many useful techniques and
technologies to assist in separation. Once a molecule is successfully isolated using various
levels of chromatographic separation, abundant modalities of mass spectrometry exist for
detailed molecular analysis of the resultant isolate. New proteomic analytical laboratories,
for example, have developed dedicated chromatography and mass spectrometry platforms
for identifying fine molecular modifications among proteins, revealing biological changes as
subtle as post-translational modifications of single proteins out of mixtures of cellular
extracts [302].
As it pertains to conditioned medium, these techniques, while tried-and-true, are often
limited technically, depending on the material to be isolated and identified. As can be seen
in Table 4.1.1, some molecules can be isolated from only a few liters of conditioned
medium, but more elusive molecules require hundreds of liters, which requires costly
infrastructure for large-scale cell growth and conditioned medium production [299]. Given
the value of certain molecules, especially those that can be developed as recombinant
protein therapeutics [303], this investment can pay off, but large-scale characterization of
the cell secretome is cost prohibitive with these methods. As we show later, genomic
technologies, when leveraged correctly, can be powerful new tools for tackling this same
problem, and offer compelling advantages in terms of cost and scale.
4.1.2. Choosing an MSC-Relevant Measure of Potency
As is clear in Table 4.1.1, every separation strategy requires a potency assay to trace the
activity of fractions of conditioned medium. For the results of the separation to be relevant,
the potency assay must be based on realistic biological phenomena, and the most valuable
potency assays are those that predict efficacy of isolated factors as modifiers of disease
processes. The most biologically relevant potency assays are low throughput, and often
entail disease modeling in animals. Often, as the potency assay is adapted to
accommodate scaling constraints of higher throughput, the biological relevance suffers -
higher throughput assays usually require the use of in vitro methods that are more easily
reproducible and less complicated than whole-organism studies [304]. In order to perform
a meaningful screen, therefore, a balance must be struck between throughput of the
potency assay and the relevance of the output. High throughput screening (HTS), used for
decades as a major modality of drug discovery, is often severely limited by the relevance of
the assays developed to accommodate the hundreds of thousands or millions of molecules
screened [305]. Add to that the fact that most screens are only testing single
concentrations of each compound in a library, and it is no wonder HTS approaches have
produced underwhelming results [306]. Ideally, the libraries of compounds screened would
be smaller and more concentrated with relevant potential hits, which could accommodate
medium- or low-throughput assays that preserve biological relevance [307-309]. As will be
seen later in this chapter, using gene expression analysis, we were able to generate a
highly enriched library of potential protein therapeutics that allowed us to use a medium-
throughput potency assay that preserved biological relevance in vivo.
Generally speaking, for an in vitro medium-throughput assay, primary cells isolated from
human subjects are superior to immortalized cell lines and primary cells from animals as
they mimic as closely as possible the behavior of human biology. Unfortunately, few
diseases can be easily modeled with primary human cells that are amenable to isolation
and manipulation with minimal perturbation of natural function. This is likely why human
peripheral blood mononuclear cells are used often in potency assays, as this fraction
contains many different circulating immune cells, including monocytes, neutrophils, NK
cells, T cells and B cells, which is a sufficient composition of cells to accurately model
immune activity in whole human blood [310]. For our purposes, we sought a potency
assay that would not only be as biologically relevant as possible, but also would reveal an
output that could be used to assess MSC activity. Fortunately, we were able to adapt an
assay developed by Nemeth and co-workers [146] to suit our own purposes [258] (see
Appendix), that leveraged PBMCs to measure the anti-inflammatory activity of MSC-CM,
with IL-1 0 as the measure of potency.
N6meth and colleagues demonstrated that MSCs, when transplanted in the context of
murine cecal ligation and puncture sepsis, are effective at protecting animals from death by
a contact- and prostaglandin-mediated upregulation of IL-10 in macrophages [146]. Based
on the apparent importance of IL-1 0 in the MSC-mediated protection of mice with sepsis,
and based on our observation that IL-1 0 is upregulated in animals treated with MSC-CM,
we hypothesized that by modifying Nemeth's assay and replacing macrophages with
PBMCs (the primary population of cells first exposed to MSC-CM upon i.v. administration),
we might see a similar increase in IL-10 secretion in PBMCs incubated with MSC-CM and
stimulated with LPS. As will be described later, we indeed observed a significant increase
in IL-10 production from PBMCs incubated with MSC-CM and then stimulated with LPS,
providing for a reproducible potency assay.
In addition to having been shown as an important intermediate in MSC and MSC-CM
therapy, IL-10 is a pleiotropic cytokine that as a measure of potency has profound
therapeutic implications. IL-10 is widely viewed as the archetypical anti-inflammatory
cytokine because of its capacity for suppressing early-phase inflammatory cytokine
production in various immune cells [265]. While it has a systemic half-life of about two
hours [311, 312], by suppressing IL-1, IL-6, IL-12 and TNF-a from DCs, macrophages and
monocytes during acute-phase inflammation, IL-10 is capable of providing significant
support during cytokine storm [313, 314]. IL-10 has been shown to suppress antigen
presentation by DCs and mediate tolerance [315, 316], regulate T cell differentiation via
modulating production of T helper cell type 1 cytokines, IL-2 and IFN-y, and helper type 2
cytokines IL-4 and IL-5 [317], and is critical for the effector function of regulatory T cells [318].
Given its broad ability to suppress inflammatory processes, IL-1 0 has been explored as a
therapeutic in a vaiety of animal disease models. It was first observed in IL-10 knockout mice
that spontaneous enterocolitis formed, implicating the important role IL-10 plays in regulating
colonic homeostasis and preventing the onset of IBD [319]. Multiple studies demonstrated that
exogenous IL-1 0 administration could prevent onset of colitis in a variety of models of colitis, but
only when given prior to disease onset [320, 321]. Later studies showed that genetically
modified L lactis that constitutively expressed IL-10 could be used as a treatment for murine
colitis [322]. Other animal disease models in which IL-1 has been shown to have an effect
include diabetes mellitus [323], experimental autoimmune encephalitis [324], pancreatitis [325],
and various models of arthritis [326, 327]. Based on the encouraging results of these animal
studies [328], IL-10 has also been tested in humans, with efforts primarily led by the former
Schering-Plough and DNAX Research Institute. Table 4.1.2 summarizes diseases in which IL-
10 has been tried therapeutically [328].
Table 4.1.2 - Human trials of interleu
Indication Trial Progression Patients Treated
Crohn's Phase I Mild to moderate
Phase 11 Therapy refractory CD
Curative resection
Rheumatoid Phase I
Arthritis Phase 11
Adult RA patients
Adult patients with moderate to
severe psoriasis
Adult patients with HCV
Adult HIV patients
kin 10 therapy
Study Conclusions
IL-10 is safe
No lasting remission with systemic
administration
High dose side effects- anemia and
headache
IL-10 is safe
63% of patients achieved ACR 20 response
compared to 10% with placebo with an IL-
10 dose of 20 pg/kg 3 times per week;
higher ACR responses were not observed
IL-10 well tolerated
In double-blind, placebo controlled studies,
modest trend towards improvement, no
lasting remission
IL-10 prevents liver fibrosis
Liver enzymes decreased, indicating lower
level of liver injury during chronic infection
IL-10 is well tolerated
IL-10 does not provide immunological or
virological benefit
Unfortunately, the clinical trial results of IL-10 therapy have not lived up to expectations.
Many assert that this can be attributed to the relatively short half-life of IL-10 [328],
especially as a treatment for diseases that require systemic administration. However, it is
clear from the animal and human studies of IL-10 that it exerts powerful effects on
inflammatory processes. IL-10 boosting strategies, therefore, that enhance endogenous
production might allow for successful use of IL-10 as an intermediate anti-inflammatory
molecule without the shortcomings of exogenous delivery. Since MSO-CM has been
shown to boost IL-10 in vitro and in vivo, we decided it would be an excellent proxy for
therapeutic activity, and an excellent potency indicator during CM stratification.
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Psoriasis
Chronic
Hepatitis C
HIV
Phase I
Phase 11
Phase I
Phase I
Phase 11
Ref
[329-
332]
[333,
334]
P35-
3378
339]
[340]
We subsequently used IL-1 0 as our biomarker for therapeutic activity, and as the next
section will describe, successfully broke down the contents of MSC-CM to elucidate novel
IL-1 0 boosting agents expressed by MSCs. As a final proxy for activity, we also wanted to
confirm that the IL-1 0 boosting that we measured in vitro was relevant in vivo, so we chose
to use a mouse potency assay involving the same pro-inflammatory ligand as we used for
the in vitro potency assay, lipopolysaccharide (LPS). LPS molecules constitute the majority
of the outer coating of gram-negative bacteria, and signal through toll-like receptor (TLR) 4
in most mammalian species to activate pro-inflammatory transcription factors such as
NFKB [341, 342]. This pathway is highly conserved across species as a first level of
defense against gram-negative microbial infection. In animals, LPS is a classical stimulant
of acute-phase inflammation, and at a high dose precipitates cytokine storm and shock
[343]. We chose to investigate this disease model not only as a proxy for therapeutic
activity of isolated MSC factors in the context of septic shock, but we also reasoned that
LPS-mediated signaling could yield a response relevant to other diseases as it does involve
extensive communication of pro- and anti-inflammatory early-phase mediators that have
also been shown to play major roles in other diseases of inflammation and autoimmunity
[344, 345]. Future work will entail further exploration of the anti-inflammatory utility of the
factors discovered in other diseases.
4.2. Enriched Protein Screening Reveals MFAP5 and PENK as
Novel Cytokine Modulators Inspired by Human Mesenchymal Stem
Cell Secretions
4.2.1. Abstract
Protein therapeutics comprise a major fraction of all administered drugs. Unfortunately,
discovering new protein therapeutics is a tedious process that relies on years of detailed
research into the nature of biological pathways to identify disease-modifying molecules.
Open-ended screening of proteomic libraries is cost prohibitive and intractable since the
majority of the human proteome has not yet been synthesized. Here we present a new
method to rationally screen for protein therapeutics that uses bioinformatics guided by
enriched genomic datasets in combination with potency assay testing. We leveraged this
method to identify four novel proteins with previously unknown anti-inflammatory
properties expressed by human bone marrow stromal cells, two of which provided a
significant survival benefit to mice challenged with lethal endotoxemic shock. Using this
enriched protein screening approach, we achieved a remarkable hit rate of 18% with
exceptional efficiency of time, expense, and labor compared to current methods of protein
discovery.
4.2.2. Introduction
The market for protein therapeutics is growing faster than for any other drug class [346,
347]. Sales last year were predicted to make up nearly one third of all drug revenues and
exceed $90B [348-350]. Despite the rapid growth, discovering new protein drugs can be
prohibitively expensive: from 2007-09, the pharmaceutical industry invested $70.6B into
research and development, yet only 11 new protein therapies were approved by the FDA
during that period [346, 347]. Discovery of new candidates has primarily relied on research
into the biology of disease and selecting agents for intervention, an inherently inefficient
process [351]. Open-ended screening approaches that assume less about the underlying
biology are impractical because establishment of proteome libraries is costly and not all
proteins synthesized in the human body can be made recombinantly [352]. These
approaches are also weak because throughput constraints require assays to be scaled,
often resulting in a loss of biological relevance and increased risk of false negatives [353].
New methodologies for identifying potential protein therapeutics that preserve biologically
relevant outputs while circumventing mechanistic understanding upfront could disrupt
current discovery strategies and offer powerful insights into novel therapeutic phenomena.
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We report here a new methodology that leverages the high biological relevance of a low-
throughput human peripheral blood mononuclear cell (PBMC) potency assay in concert
with virtual candidate enrichment using gene expression profiling to identify potential
protein therapeutics naturally expressed by bone marrow stromal cells (BMSCs). BMSCs
are stem-like cells that are being explored clinically as a novel therapeutic for a variety of
inflammatory and autoimmune disease [267]. The implementation of this methodology led,
in a matter of months and for under $50,000, to the discovery of two novel proteins,
microfibrillar associated protein 5 (MFAP5) and unprocessed proenkephalin (PENK), that
when given to mice challenged with the classical TLR ligand and acute phase agonist LPS,
reversed the cytokine storm and provided a significant survival benefit comparable with the
gold-standard anti-inflammatory biologic, anti-TNF-a. The design of our approach (referred
to as enriched protein screening, EPS) is shown and described in Figure 4.2.1a.
4.2.3. Materials and Methods
4.2.3.1. Statistics
Unless otherwise noted, all experiments were repeated in quadruplicate, and all data were
assessed for significance using a paired, two-tail Student's T test.
4.2.3.2. Cell Culture and Conditioned Medium
BMSCs were isolated, purified, grown and characterized, and fibroblasts grown as
described previously [41, 258]. All BMSCs were used at passage 2-5. The conditioned
medium was also collected and concentrated as described previously [42]. For the
BMSCps conditioned medium and cells used for gene expression analysis, BMSCs were
grown to >80% confluence and rinsed twice with PBS. BMSC or fibroblast expansion
medium supplemented with 1 [tg/mL LPS (E. coli 0111:B4; Sigma, St. Louis, MO) was then
added to the cells for 24 hours, at which time the cells were rinsed with PBS twice again
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and incubated for an additional 24 hours with serum-free DMEM to produce conditioned
medium. By convention, 1X refers to the concentration of conditioned medium achieved
when 15 mL of conditioning medium was incubated in the presence of 2x1O' cells for 24
hours, collected, and concentrated to a final volume of 1 mL.
4.2.3.3. Peripheral Blood Mononuclear Cell Potency Assay
The assay was performed as before ([258]; see Appendix). Approval for the collection of
blood from healthy volunteers was obtained from the Institutional Review Board of
Massachusetts General Hospital. For the majority of the experiments, the potency assay
was terminated at 5 hours for IL-1 0 analysis.
4.2.3.4. Gene Expression Analysis
Gene expression was evaluated using Affymetrix GeneChip@ Human Genome U133 Plus
2.0 Arrays (Affymetrix, Santa Clara, CA). Array quality was assessed using the
R/Bioconductor package [354]. All arrays passed visual inspection and no technical
outliers were identified (n=3 arrays per cell type). Raw CEL files were processed using the
robust multiarray average (RMA) algorithm [355]. To identify genes correlating with the
observed phenotypic groups, we used limma [356] to fit a statistical linear model to the
data and then tested for differential gene expression in the contrasts of interest: FB vs.
BMSC; BMSC vs. LPS. Results were adjusted for multiple testing using the Benjamini and
Hochberg (BH) method [357], and significance was determined using a False-Discovery-
Rate cutoff of less than 1 %. All genes identified to be upregulated in BMSCs compared to
FBs and either expressed equally or upregulated in BMSCJS compared to BMSCs were
then analyzed by literature review for definitive evidence of production of a secreted protein
by human cells to generate the list of genes reported here. Independent analysis
conducted in collaboration with a second computational biology facility confirmed these
same results with >95% overlap of secreted proteins identified via literature review.
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Recombinant Protein Screen
Recombinant proteins were acquired from a commercial vendor (Abnova, Taipei, Taiwan).
The proteins were diluted in PBS and added to the PBMC potency assay to achieve a
range of final concentrations spanning -1 [tg/mL to -0.01 ng/mL.
4.2.3.6. ELISAs and Western Blots
The ELISA kits used were provided by commercial vendors and were used according to
the manufacturers' instructions (IL-10 in cell supematants: BD, Franklin Lakes, NJ;
LGALS3BP: Abnova, Taipei, Taiwan; IL-10 and TNF-ca from animal serum: R&D Systems,
Minneapolis, MN). To blot for GALNT1, MFAP5 and PENK, FB-CM, BMSC-CM and
BMSCus-CM were run out using protein gel electrophoresis (Pierce, Rockford, IL) followed
by blotting using detection antibodies (Sigma, St Louis, MO) applied at a dilution of 1:500
(GALNT1 and MFAP5) or 1:100 (PENK), and corresponding secondary antibodies (anti-
rabbit for GALNT1 and MFAP5 and anti-goat for PENK) conjugated with HRP (Sigma, St.
Louis, MO). For the LGALS3BP ELISA and the MFAP5 blot, 1X conditioned media were
used, and for the GALNT1 and PENK blots, 20X conditioned media were used.
4.2.3.7. Mass Spectrometry
Mass spectrometry was performed at the Mass Spectrometry Core facility of the Beth
Israel Deaconess Medical Center at Harvard Medical School as previously described [358].
1OX samples of BMSC-CM, FB-CM and BMSCps-CM were initially separated by SDS-
PAGE and bands were excised and trypsin digested for analysis via tandem LC/MS/MS.
The false discovery rate (FDR) for peptide identifications was - 1.5% and less than 0.5%
for protein identifications.
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4.2.3.5.
4.2.3.8. In Vivo Mouse Assay
All procedures were performed in accordance with the animal rights policies of the
Massachusetts General Hospital Subcommittee on Research Animal Care. For the sub-
lethal LPS model, eight week old female BALB/cJ mice (n 3) (Jackson Laboratories, Bar
Harbor, ME) were administered an initial dose of either vehicle or one of the experimental
therapies IP: 200 [tL of saline (vehicle), or 3 [tg of protein (e.g. GALNT1, LGALS3BP,
MFAP5 or PENK) diluted in 200 [L of saline, or 1 mL of 1X BMSC-CM. 16 hours later, the
mice received a second dose of either vehicle or therapy in conjunction with a dose of 100
ptg of LPS (E. coli 0111:B4; Sigma, St. Louis, MO) diluted in physiological saline. 48 hours
later, the mice were sacrificed and tissue and blood were collected for analysis. The serum
was tested for the presence of IL-1 0 and TNF-a via ELISA and the lungs, livers and kidneys
of the animals were preserved for hematoxylin and eosin staining. For the lethal LPS
model, eight week old female BALB/cJ mice (n 5) were co-administered a lethal dose of
LPS (350 [xg LPS in 100 ItL physiological saline) and either vehicle (negative control), 5 ptg
anti-TNF-a (positive control; R&D Systems, Minneapolis, MN), 4 [tg MFAP5 diluted in 100
[tL of physiological saline, or 4 [g of PENK diluted in 100 [tL of physiological saline. The
mice were monitored for survival for seven days (168 hours).
4.2.4. Results
We began this study with the development of an in vitro potency assay based on primary
human PBMCs to evaluate the bulk anti-inflammatory activity of BMSC-CM (Figure
4.2.1b). We observed that LPS-stimulated production of IL-10 by human PBMCs
increased significantly when they were incubated with BMSC-CM compared to vehicle
control (Figure 4.2.1c). The upregulation of IL-1 0 release was time- and dose-dependent
(Figure 4.2.2a-b) and was induced by protease-sensitive constituents of BMSC-CM
(Figure 4.2.2c). To identify and purify individual factors responsible for this IL-1 0 response,
we first attempted liquid chromatography (LC) and mass spectrometry (MS) analysis. We
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successfully identified regions of activity with LC separation based on size and charge, but
MS failed to elucidate specific factors even after concentrating and purifying BMSC-CM
from >1x109 cells (Figure 4.2.3a-b). This led us to seek an alternative approach to
screening BMSC secreted factors that would be more time, labor, and cost effective.
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Figure 4.2.1 - Enriched protein screening (EPS) of BMSC-CM: approach, assay development and gene
expression profiling. (a) Generalized schematic of EPS methodology. Protein products are derived from
various cell types in the form of conditioned media and screened for activity in an in vitro potency assay.
Based on the activity of the conditioned media from the cells, hierarchical comparative gene expression
profiling is performed to select for genes uniquely upregulated in the cell type with the highest activity in the
potency assay. Recombinant protein products of the enriched gene list are then screened in a potency
assay and the candidates with the highest activity are assessed for activity in vivo. (b) The in vitro potency
assay for this study. This assay entails incubating primary human peripheral blood mononuclear cells
(PBMCs) in the presence of protein products (e.g. conditioned medium from a cell) for 16 hours, followed by
stimulation of the PBMCs with LPS for five hours, and measurement of IL-1 0 secretion into the supernatant
via ELISA. (c) Time course of IL-1 0 expression from PBMCs when incubated with either bone marrow
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stromal cell conditioned medium (BMSC-CM) or unconditioned medium (DMEM) in the potency assay. (d)
Comparison of potency assay activity of conditioned medium from normal human dermal fibroblasts (FB-
CM), BMSCs (BMSC-CM) and BMSCs preincubated with LPS prior to conditioning (BMSqoS-CM). * p <
0.001 compared to FB-CM, ** p < 0.001 compared to BMSC-CM. (e) Schematic of the gene expression
comparison scheme. Genes correlating with anti-inflammatory activity were selected by taking the
intersection of the sets of all genes upregulated in BMSCs compared to FBs and all genes expressed equally
or upregulated in BMSCps compared to BMSCs. (t) Gene expression profiling revealed 22 genes
responsible for secreted proteins that were upregulated by BMSCs stimulated with LPS compared to
BMSCs and FBs.
To circumvent individually screening the hundreds of proteins secreted by BMSCs [42,
359], we developed a comparative gene expression scheme that enabled us to rationally
enrich for candidate proteins that contribute to the anti-inflammatory activity of BMSC-CM.
To this end, we first sought to identify a "BMSC signature" in terms of BMSC genes that
were associated with IL-10 upregulation in our potency assay. This led us to seek a
comparative BMSC analog that was likely to express many similar genes as BMSCs, but
lacked activity in the potency assay. We tested the CM from a similar stromal cell, normal
human skin fibroblasts (FB), and found that FB-CM did not cause a significant increase in
IL-10 expression in the potency assay (Figure 4.2.1d). Comparison of gene expression of
BMSCs and FBs, yielded a list of -500 genes uniquely upregulated in BMSCs. One
additional, but essential comparative group, was then included to refine the "BMSC
signature".
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Figure 4.2.2 - Characterization of IL-1 0 assay and optimization of BMSC preconditioning. (a) Kinetics of IL-
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10 secretion by PBMCs incubated with or without BMSC-CM and stimulated with LPS. (b) Dose response of
the potency assay to increasing concentration of BMSC-CM. 1X CM was either diluted or concentrated
further to generate the different concentrations. * p < 0.001 compared to DMEM. (c) Effect of proteinase K
on the activity of BMSC-CM in the potency assay. (d) Effects of preincubating MSCs with various factors on
the activity of BMSC-CM in the potency assay.
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Figure 4.2.3 - Liquid chromatography of BMSC-CM. Chromatography was used to fractionate the BMSC-
CM into 0.5 mL fractions and then the fractions were evaluated for IL-1 0 activity in the potency assay. (a)
Fractions generated by size exclusion chromatography. (b) Fractions generated by anion exchange
chromatography.
We perturbed the genomic signature of BMSCs by establishing conditions under which the
activity of the BMSC-CM was enhanced. BMSCs are known to display a number of
surface cytokine and toll-like receptors that have been implicated in their
immunomodulatory phenotype [360]. We pre-stimulated BMSCs with a selection of the
cognate ligands for these receptors for 24 hours prior to conditioning. We discovered that
the BMSC-CM from cells that were pre-stimulated with LIPS exhibited significantly higher
activity in the potency assay (Figure 4.2.1d and 4.2.2d). We used this information to
further refine our analysis by cross-referencing our list of BMSC-specific genes with genes
that were maintained at the same level or significantly upregulated by BMSCs stimulated
with LIPS (BMSCos) compared to BMSCs. This comparison revealed 139 genes (Figure
4.2.1e). We then conducted a literature search to determine which of these genes
correspond to a secreted protein, yielding a highly enriched set of 22 genes (Figure 4.2.11).
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Figure 4.2.4 - Screening of the enriched recombinant protein candidates and assessment of BMSC
secretion of the candidate proteins. (a) Enriched recombinant protein screen using the potency assay. (b)
EUSA and western blotting of FB-CM, BMSC-CM and BMSCLPS-CM for LGALS3BP, MFAP5, GALNT1 and
PENK. * p < 0.001 compared to FB-CM. (c) Partial list of proteins contained in 1 OX FB-CM, BMSC-CM, and
BMSCLPS-CM detected by proteomic mass spectrometry.
We next assembled a purified recombinant protein library corresponding to the 22
candidate genes identified by our enrichment technique. We individually screened the
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proteins in our potency assay using a range of physiologically-relevant concentrations and
found that 4 of the 22 screened proteins successfully upregulated IL-10 secretion when
present at -100 nM concentrations (Figure 4.2.4a). To test whether BMSC-CM contained
the four proteins, polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1), galectin-3-
binding protein (LGALS3BP), microfibrillar-associated protein 5 (MFAP5) and proenkephalin
(PENK), we performed semi-quantitative Western blots for GALNT1, MFAP5 and PENK,
and used a quantitative ELISA for LGALS3BP (Figure 4.2.4b). Clear bands were observed
for MFAP5 and ELISA results showed LGALS3BP to be present at ng/mL concentrations in
the BMSC-CM. GALNT1 and PENK were not present at detectable levels, even when the
CM was concentrated 100-fold. This may be due to the fact that GALNT1 is only
hypothesized to be secreted [361], and PENK is a pro-protein that is mostly processed into
smaller peptide derivatives that might not react with the PENK antibody we used [362]. We
also performed proteomic LC/MS on bulk BMSC-CM and identified several of the 22
proteins in our enriched library, including LGALS3BP (Figure 4.2.4c). Nevertheless, LC/MS
failed to discem 18 of the 22 proteins (81 %) from the enriched library, including GALNT1,
MFAP5 and PENK. Taken together, these results demonstrate an unprecedented hit rate of
protein discovery via EPS (18%), which is several orders of magnitude higher than
traditional high throughput approaches that achieve in vitro rates on the order of 0.03-0.2%
[363-365].
We then tested the four hits from the enriched recombinant protein screen for activity in
vivo in animals challenged with a sub-lethal dose of LPS (Figure 4.2.5a). Significantly
elevated serum IL-10 levels were observed in LPS-treated mice receiving BMSC-CM,
GALNT1, MFAP5 and PENK compared to baseline vehicle control (saline), but no IL-10
response from LGALS3BP (Figure 4.2.5b). Serum TNF-a was also significantly
suppressed in mice receiving BMSC-CM, LGALS3BP, MFAP5 and PENK, but not GALNT1
(Figure 4.2.5c). In addition, MFAP5 and PENK demonstrated superior TNF-a suppression
compared to BMSC-CM. These results suggest that the different factors may influence
different pathways, and it is conceivable that combinations of these factors could be used
to treat multiple pathways in parallel.
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Figure 4.2.5 - In vivo hit screen and survival study. (a) Schematic of the in vivo LPS assay. Proteins were
administered intraperitoneal (IP) at the concentration that elicited the strongest effectin vitro, followed by IP
administration of LPS in conjunction with a second dose of the proteins 16 hours later. Two days after the
combined LPS and second protein dose, the mice were sacrificed and assessed for changes in serum
cytokines and tissue histology. (b) Serum IL-10 levels of BALB/cJ mice subjected to the in vivo LPS assay. *
p < 0.001 compared to saline. (c) Serum TNF-a levels of BALB/cJ mice subjected to the in vivo LPS assay. *
p < 0.001 compared to saline, *' p < 0.05 compared to BMSC-CM. (d) Representative micrographs of lung
tissue from mice subjected to the in vivo LPS assay stained with hematoxylin and eosin. (e) Survival of mice
subjected to a lethal dose of LPS i.p. (350 sg) concurrently with i.p. saline vehicle (bold dark blue line, n=20),
6 [tg Anti-TNF-a antibody (thin dark blue line, n=5), 4 pg PENK (bold light blue line, n=5) or 4 pg MFAP5 (thin
light blue line, n=5). * p < 0.005 compared to vehicle control, ** p < 0.001 compared to vehicle control. Scale
bar = 200 pm.
The effects of cytokine modulation were apparent in the lung histology of the animals
(Figure 4.2.5d). In vehicle treated animals, edema, inflammatory infiltrate and alveolar
collapse were evident in all lung fields. MFAP5 showed superior lung protection,
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preventing widespread inflammatory cell infiltrate and edema, thereby preserving the
structure of the alveoli in the majority of the lungs. PENK, BMSC-CM and GALNT1 showed
moderate protection with apparent inflammatory infiltrate, emphysematous changes and
alveolar wall thickening, but no frank alveolar collapse. Based on these results, we then
proceeded to test the two most promising proteins, MFAP5 and PENK in mice challenged
with a lethal dose of LPS. Compared to anti-TNF-a, the gold-standard anti-inflammatory
therapy for human use [366], both proteins exhibited similar protection and provided a
significant survival benefit (Figure 4.2.5e).
4.2.5. Discussion
Here we present two novel candidate anti-inflammatory protein therapeutics, both naturally
expressed by BMSCs and identified using EPS. Neither have been previously reported to
be secreted by BMSCs endogenously nor to contribute to the activity of BMSC therapy
[256]. Moreover, neither have been previously demonstrated to possess potent anti-
inflammatory activity. Proenkephalin A (PENK; a.k.a. PEA) is the precursor of the
enkephalin opioid peptides and is proteolytically processed to yield Met-enkephalin, Leu-
enkephalin, Met-enkephalin-Arg-Phe, Metenkephalin-Arg-Gly-Leu, enkelytin and PENK-
derived peptides (Table 4.2.1) [367].
Table 4.2.1 - Peptide products of proenkephalin (PENK)
Name Amino Acid Sequence MW (da)
Met-enkephalin Tyr-Gly-Gly-Phe-Met (SEQ ID NO. 14) 576
Leu-enkephalin Tyr-Gly-Gly-Phe-Leu (SEQ ID NO. 15) 554
Peptide F (human) Tvr-GIv-GIv-Phe-Met-Lys-Lys-Met-Asp-Glu-Leu-Tyr-Pro-Met-Glu-Pro-Glu- 3846
Glu-Glu-Ala-Asn-Gly-Ser-Glu-ne-Leu-AJa-Lys-Arg-Tyr-Gly-Gly-Phe-Met (SEQ
ID NO.16)
Peptide E (human and bovine) Tyr-Gly-Glv-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln- 3157
Lys-Arg-Tyr-GIy-GIly-Phe-Leu (SEQ ID NO. 17)
Peptide B (human) Phe-Ala-Glu-Ala-Leu-Pro-Ser-Asp-Glu-Glu-Gly-Glu-Ser-Tyr-Ser-Lys-Glu-Val- 3655
Pro-Glu-Met-Glu-Lys-Arg-Tvr-Gly-GIy-Phe-Met-Arg-Phe (SEQ ID NO. 18)
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Cleavage of PENK by proteases takes place at dibasic, lysine-lysine, amino acid residues.
It is expressed in specific sites in the brain and certain cells of the adrenal medulla and the
immune system, which is increased at the gene expression level in response to
inflammation [368]. The physiological relevance of the responsiveness of the PENK gene in
these sites remains unclear. The concentration of PENK-derived peptides in the
unstimulated bovine adrenal medulla exceeds 200 [tg per gram of granule protein in
secretory vesicles of chromaffin cells [369]. It is worthwhile to note that, except in the
setting of meningococcemia, inflammation of the adrenal gland is a medical rarity.
Peptides with antimicrobial activity but no known neuropeptide function have been
identified in the adrenal medullary chromaffin cell discharge. They include enkelytin and
peptide B from PENK [370]. Investigators have proposed that PENK contains
neuropeptides, antibacterial peptides, and immune stimulatory peptides [371]. In addition
to the neurohormone properties of PEAPs [372], numerous studies have demonstrated that
PEAPs are secreted in various forms by cells in the immune system including T cells [373],
neutrophils [374], and monocytes [375]. The effects of enkephalins on various activities of
immune cells (chemotaxis, cytotoxicity, immunoglobulin synthesis), which bear opioid
receptors, have been described. PEAPs have been shown to promote lymphocyte
chemotaxis [376], suppress T cell activation when secreted by colon cancer cells [377],
possess anti-bacterial properties [370, 378], and depending on the concentration, induce or
suppress blastogenesis of human lymphocytes [379]. However, there have been no
reports of PENK altering cytokine secretion from immune cells when administered directly
in a purified form [380]. One study using PENK-deficient mice reported that T cells could
produce IFN-y and TNF-a but not IL-4 or IL-1 0 [381]. However, the study did not show a
causal link between PENK and these cytokines. Overall, these studies might partially
explain the immunomodulatory effects of PENK we have seen here, although a causal
relationship between PENK and inflammatory cytokine modulation has not been previously
demonstrated.
MFAP5 is an ECM glycoprotein localized to microfibrils and associated with elastin
networks. It is a highly hydrophilic molecule consisting of two distinct domains: a cysteine-
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free acidic N-terminal half, and a cysteine-rich basic C-terminal half. It has been found to
have significant homology (57%) with MFAP2 (MAPG-1) [382], in particular with respect to
the cysteine rich region. A series of 7 cysteines near to the center of both molecules
precisely align when their sequences are compared, and the cysteine separation distances
are highly conserved. Evidence of its relationship with the immune system is limited.
MFAP5 binds fibrillin-1 and -2 at the C-terminus, as well as to other proteins containing
EGF-like repeats [383]. It contains an RGD integrin-binding motif and has been shown to
bind integrin [384]. MFAP5 has also been shown to interact with the Notch receptor
pathway [385]. Conflicting accounts describe this interaction as either inhibitory [386] or
activating [385], so the mechanisms by which MFAP5 binds Notch and instigates
downstream signaling are yet unknown. Of note, to-date there have been no accounts of
MFAP5 influencing immune processes, and its connection to human disease has not been
established. It is interesting to note that the MFAP5 gene is located in the natural killer
gene complex, and this location is highly conserved across species. Nevertheless, the
strongest evidence that MFAP5 might play an endogenous role in immune function is seen
in its relationship to cancer. It has been shown that serum MFAP5 (also known as MAGP-
2) levels correlate with poor prognosis in patients with ovarian cancer [387]. In the same
study, it was shown that tumor cells constitutively express MFAP5 in vitro, and could be
the source of MFAP5 secretion in vivo [387]. In all, these data suggest that in addition to
identifying potentially therapeutic molecules, our EPS approach has also revealed as yet
unknown biology, both in terms of the implications of endogenous secretion of PENK and
MFAP5 by BMSCs, and the anti-inflammatory role these two proteins might naturally serve
in vivo. Judging by their size and the pattern of secretion by BMSCs and other cells, it is
conceivable that MFAP5 and derivatives of PENK are bona fide cytokines, and may play
important roles in the modulation of other immune functions besides inflammation [369,
388].
EPS has several advantages over traditional methods for protein drug discovery, making it
a powerful new strategy for uncovering new therapies. First, by choosing a therapeutic
output as the sole determinant of candidate activity (i.e. IL-10 upregulation), this approach
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allowed us to screen without any hypotheses as to the nature or existence of receptor
targets and bypass the years of research required to uncover intermediate ligand-receptor
interactions. Second, EPS entails enrichment of a candidate population by design and
thereby achieved an in vivo hit rate of 18% from our modest and inexpensive library of 22
recombinant proteins. This hit rate is several orders of magnitude higher than traditional
HTS approaches that have been reported to exhibit in vitro rates on the order of 0.03-0.2%
[363-365]. Finally, by using proteins as the basis for our screen, we ensured that all of our
hits would be useful both as potential natural therapeutics, and as tools to uncover new
anti-inflammatory pathways that have not yet been characterized.
We posit EPS can be applied to other cell types as well to reveal novel therapeutic
molecules. EPS leverages the advantage of learning directly from the natural protein
source to uncover new ways and means of modulating complex physiological processes to
yield desirable outcomes. Also, we designed EPS to be modular such that the cell(s) and
the assay(s) can be substituted to reveal genes that correlate with many diverse
phenotypes. With the development of additional assays, enrichment of new recombinant
libraries, and identification of novel potent secreted molecules, new classes of protein
therapeutics could be discovered using EPS to treat difficult diseases in a natural and
biologically relevant way.
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5. Conclusions
The primary goal of this thesis was to build upon the current knowledge of MSCs and
explore further the therapeutic utility of MSC secreted factors in a variety of inflammatory
diseases. While pursuing this goal, my colleagues and I discovered that MSC secreted
factors, independent of cell transplantation, were capable of providing significant protection
to rats subjected to acute kidney injury. We found that the concentration of CM and dose
regimen used provided a superior survival benefit and protection compared to other
studies of MSC transplantation and MSC-CM administration in AKI. This finding was
consistent with the work of my predecessors, and further suggested the general utility of
MSC-CM. From these studies, we are confident in concluding that the mechanisms of
MSC-CM therapy must share similarities in FHF and AKI, and could very well provide for
significant support in other diseases with comparable underlying hallmarks of
pathophysiology.
We also set out through the course of this thesis to begin to develop the original blood-
contacting platform prototyped in our lab for clinical use, and make vertical advances
towards successful translation. By seeding MSCs in standard hollow-fiber bioreactors
(repurposed dialyzers) and subjecting these devices to conditions that mimic clinical
operation, we were able to confirm that MSCs adhere and grow on polyethersulfone hollow
fibers, are metabolically normal, do not differentiate during operation, and produce
considerable and measurable amounts of proteins that are collectively therapeutically
potent. This information will prove useful as we continue to test this device in large animals
in preparation for human clinical trials.
In the final part of this thesis, we expanded in an orthogonal direction from our previous
work, and began to regard the MSC-CM as a valuable source for mining potential protein
therapeutics. Previous attempts to accomplish the same have provided valuable insight
into the soluble mechanisms of MSC therapy, however never before had novel protein
mediators been discovered to be secreted by MSCs. By developing a new methodology
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for enriching the library of secreted factors from MSCs via comparative gene expression,
we were able to identify multiple novel proteins that exhibit potent antHnflammatory effects
on human blood cells and in mice. Based on the potency of these molecules in vitro and in
vivo, we are planning to pursue clinical translation with the goal of developing new protein
therapeutics for inflammatory and autoimmune disease.
In all, the contents in this thesis have confirmed the findings of many groups that MSCs are
extraordinary cells with meaningful biological and therapeutic implications. Continued
efforts to optimize transplantation of the cells to maximize the conveyance of secreted
factors holds great promise for the use of MSCs as a direct injectable in a variety of chronic
inflammatory and autoimmune diseases. In addition, the development of new means for
quickly administering MSC secreted factors in the context of acute disease, where the
kinetics of engraftment and potential side effects of large doses of MSCs make
transplantation unfavorable, will continue to expand the possible diseases in which MSCs
might make a therapeutic difference. Finally, if our method for mining therapeutic cells for
potential protein therapeutics can serve as the basis for new protein therapeutic discovery
platforms, great advances are possible in the field of protein drugs, hopefully allowing for
better therapies to be developed based on the natural processes of cellular
communication. Together, these findings and discoveries hold great promise in
contributing to better therapies for inflammatory and autoimmune disease, and will
hopefully reveal new, as yet undiscovered facets of disease pathophysiology and
resolution.
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7. Appendix
7.1. A Mesenchymal Stem Cell Potency Assay
7.1.1. Abstract
Mesenchymal stem cells (MSCs) are capable of modulating the immune system and have
been used to successfully treat a variety of inflammatory diseases in pre-clinical studies.
Recent evidence has implicated paracrine signaling as the predominant mechanism of
MSC therapeutic activity. We have shown in models of inflammatory organ failure that the
factors secreted by MSCs are capable of enhancing survival, downregulating inflammation,
and promoting endogenous repair programs that lead to the reversal of these diseases. As
a marker of disease resolution, we have observed an increase in serum IL-10 when MSC-
conditioned medium (MSC-CM) or lysate (MSC-Ly) are administered in vivo. Here we
present an in vitro model of IL-10 release from blood cells that recapitulates this in vivo
phenomenon. This assay provides a powerful tool in analyzing the potency of MSCrCM
and MSC lysate, as well as characterizing the interaction between MSC-CM and target
cells in the blood.
7.1.2. Introduction
Bone marrow mesenchymal stem cells (MSCs) are resident non-hematopoietic progenitor
cells that possess potent immunomodulatory abilities [99, 126, 128]. Allogeneic MSC
transplants have been used to successfully treat hematological [13, 128], cardiovascular
[108, 389], as well as neurological [390, 391] and inherited diseases [37, 392] in preclinical
studies, and allogeneic transplantation of MSCs has been approved as a clinical treatment
for severe GvHD [393]. Recent studies involving MSC transplantation have revealed that
the therapeutic activity of these grafts is independent of differentiation, and paracrine
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interactions of MSCs with tissue and immune cells provide the majority of therapeutic
benefit [41, 42, 281, 394, 395].
We have found administration of concentrated MSC conditioned medium (MSC-
CM) or MSC lysate (MSC-Ly) can reproduce the effects of a MSC graft in vivo and
significantly increase serum IL-10 levels in two animal models [41, 42]. IL-10 is a well-
known anti-inflammatory cytokine that can inhibit the secretion of pro-inflammatory
cytokines and protect cells from apoptosis and necrosis in the context of acute
inflammation [146, 265, 273]. we have determined that MSC-CM and lysate also
substantially enhance IL-10 secretion by peripheral blood mononuclear cells (PBMCs) in
vitro, and have developed an assay based on this discovery. This assay allows for rapid
and reproducible assessment of the potency of MSCs and MSC molecular products in a
manner relevant to animal and human testing of cell therapy.
Conditioned medium and cell lysate are derived from human MSC cultures and can
subsequently be used for both in vitro and in vivo experimentation (see Figure Al). Below
we provide methods for an ELISA-based IL-1 0 assay for in vitro testing, a powerful tool to
aid in determining the efficacy and underlying paracrine mechanisms of MSC transplants
and MSC-based therapies.
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Figure Al - Schematic of in vitro and in vivo potency tests of MSC-derived materials.
7.1.3. Materials
7.1.3.1. Isolation of MSCs from whole marrow and cell culture
1. Whole bone marrow aspirate: can be obtained commercially (Lonza) or from a
consented human donor.
2. Phosphate Buffered Saline (PBS). (See Note 1)
3. Ficoll-Paque Density 1.077g/mL (GE Healthcare).
4. Table-top centrifuge capable of 1500g.
5. Hemocytometer and microscope, or other method capable of determining cell
count.
6. Human MSC medium: a-Minimum Essential Medium Eagle (Sigma Aldrich)
supplemented with 15% (v/v) Fetal Bovine Serum (HyClone), 2% (v/v) Penicillin
Streptomycin Solution (GIBCO), 1 ug/ml Gentamicin (Sigma Aldrich), 1 ng/ml bFGF
(R&D Systems). Store at 4*C.
7. 370C incubator.
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7.1.3.2. Collection, concentration, and storage of MSC-CM
1. Conditioning Medium: Dulbecco's Modified Essential Medium (Sigma Aldrich)
supplemented with 0.5% (w/v) bovine serum albumin, and 2% (v/v) Penicillin
Streptomycin Solution (GIBCO).
2. 1X Trypsin prepared from 1OX 0.5% Trypsin-EDTA (GIBCO).
3. Hemocytometer.
4. For small volume of MSC-CM: 3kDa Centrifugal Filters (Amicon Ultra Ultracel-3K,
Cat No. UFC800396). Centrifuge capable of spinning at 4000g.
5. For large volume of MSC-CM: Amicon pressure concentrator (no longer
manufactured), pressurized nitrogen gas and 3 kDa regenerated cellulose
ultrafiltration membranes (Millipore Ultracel).
6. +40C freezer for storage.
7.1.3.3. Preparation of MSC lysate
1. Sonicator.
2. Benchtop Centrifuge capable of 1500g.
3. +40C freezer for storage.
7.1.3.4. Isolation of PBMC's from whole blood
1. Fresh whole blood from consenting donor.
2. PBS.
3. Ficoll-Paque Density 1.077g/mL (GE Healthcare).
4. C-10 medium: 500 mL 1X RPMI Medium (GIBCO 1650), 50 mL inactivated Fetal
Bovine Serum, 6 mL MEM Non-Essential Amino Acids Solution 10mM 1OOX (GIBCO
Cat No. 1140-050), 6 mL 1OOX Sodium Pyruvate (GIBCO 11360), 6 mL glutamate, 6
mL Penicillin Streptomycin Solution (GIBCO 15140), 6 mL Sodium Bicarbonate, 3
mL Betamercaptoethanol. Sterilize with Coming Bottle Top Filter or other means of
sterilization. Store at 40C.
5. Centrifuge capable of spinning at 1500g.
6. 96-well plate.
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7. 370C incubator.
7.1.3.5. Preparation of samples and stimulation with LPS
1. 96-well plate seeded with 50 pL per well at 2x106 PBMCs/mL
2. MSC-CM and lysate, 50pL per well.
3. LPS (E. coli 0111:B4, Sigma-Aldrich L4391) at 30pg/mL, 50pL per well. Stock
solution is diluted in C10 medium.
4. 370C incubator.
5. -80*C freezer.
7.1.3.6. ELISA and Analysis of Results
1. BD OptEIAm Human IL-1 0 ELISA Set and recommended buffers and solutions, or
other Human IL-1 0 ELISA kit.
2. BD Falcone Microtestm 96-Well EUSA Plate or other high-binding EUSA Plate.
3. Plate reader (spectrophotometer) capable of reading at indicated wavelengths in
EUSA kit (450 nm with correction at 570 nm for BD OptEIAN Human IL-1 0 ELISA
set).
4. Microsoft Excel, or other program capable of processing data from
spectrophotometer.
7.1.4. Methods
Overview: MSC-CM or lysate is prepared and added to PBMCs freshly isolated from whole
blood and plated in a 96-well plate. As a mock cell control, we perform the assay with CM
and/or lysates from fibroblasts. The plate is incubated overnight at 370C for 16-18 hours.
The PBMCs are then stimulated with LPS for 5 hours, at which time the plate is centrifuged
and the supematant stored for ELISA (See Figure A2).
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Figure A2 - Summary of In Vitro Inflammation Assay for the testing of MSC-derived factors.
7.1.4.1. Isolation of MSC's from whole bone marrow
Whole bone marrow centrifuged with Ficoll results in a pattern comparable to that of
centrifuged whole blood; the corresponding "buffy coat" is enriched with MSCs. This layer
is collected, counted, and plated on tissue culture polystyrene. The purity of MSCs
isolated from whole bone marrow is relatively high due to their ability to differentially adhere
to cell culture substrates compared to other hematopoietic marrow cells. Subsequent
medium changes eliminate hematopoietic cells and other non-adherent cells. The identity
of MSCs can be confirmed through phenotype and multipotency analysis using flow
cytometry or differentiation media, respectively. (See Note 3)
1. Wash bone marrow with equivalent volume of PBS, thus diluting the bone marrow
1:2. Prepare 5 mL Ficoll for each 10 mL of diluted bone marrow. Add diluted whole
bone marrow slowly; avoid disturbance of the boundary between Ficoll and marrow.
(See Note 1)
2. Spin 30 minutes at 1500gwith no brake. Collect the resulting mononuclear cell layer
and wash with 5 mL PBS.
3. Spin 10 minutes at 1500g, high brake. Resuspend pellet in 1 mL hMSC medium.
Determine cell count and seed at a density of 1-10x10 3 cells/cm 2.
4. Let cells adhere and grow for 10 days. Perform first medium change at day 10; the
following medium change is done at day 17. Subsequent medium changes should be
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performed at a frequency of every 3 or 4 days. Cells are typically used between
passages 1-6.
7.1.4.2. Collection, concentration, and storage of MSC-CM
By convention, 1X MSC-CM is defined as conditioned medium from 2 million cells
concentrated to 1 mL of volume. MSCs are incubated for 24 hours in conditioning medium
and concentrated to 1X. For small volumes, centrifugal filter tubes can be used. For larger
volumes, the Amicon pressure concentrator and pressurized nitrogen gas offers a more
efficient method.
1. Perform medium change on MSC cultures with two PBS washes. Add conditioning
medium, incubate for 24 hours. (See Note 4)
2. Collect MSC-CM. Trypsinize cells; determine cell count and final volume of 1X
MSC-CM.
For small volumes:
3. Add 4 mL PBS to centrifugal filter tube. Let centrifuge spin to 4000g for a few
minutes for the PBS to run through the filter to remove residual glycerin in the
ultrafiftration membrane. Discard the PBS in both compartments of the centrifugal
filters.
4. Add 4 mL MSC-CM under sterile conditions and spin at 4000g for 5-15 minutes.
Discard flow through and fill the centrifugal filter tube with new MSC-CM. Pipette
the conditioned medium up and down to wash the filter and lessen congestion of
the filter with proteins. Repeat process until the desired volume is reached.
For large volumes:
5. Sterilize the ultrafiltration membrane with 70% ethanol and let dry. Assemble
pressure concentrator according to manufacturer instructions. Place pressure
concentrator onto stir plate and prepare a waste bottle.
6. Run 20 mL of PBS through the concentrator.
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7. Discard waste and add MSC-CM. Monitor waste level in the bottle to determine the
volume of MSC-CM.
8. Let run until desired final volume is reached. Disconnect and depressurize
concentrator.
7.1.4.3. Preparation of MSC lysate
While cell lysate can be obtained through lysate buffers and other chemical means,
sonication, which causes physical disruption of the cell membrane, provides pure lysate
without chemical contaminant and possible confounding factors.
1. Trypsize MSCs and pellet in tabletop centrifuge at 1000g.
2. Discard supernatant and gently layer 1 mL PBS per 2X1 06 cells on top of cell pellet.
To visualize lysis, do not resuspend cells into solution.
3. Sonicate cell pellet at 3 A.U. for 5 seconds with 3 pulses and collect in ice.
4. Centrifuge lysate at 2000g for 2 minutes to precipitate membrane fragments. Retain
the solution phase. The solution phase from this process is considered MSC-Ly.
7.1.4.4. Isolation of PBMCs from whole blood
1. Calculate the number of wells needed to conduct the assay to estimate the amount
of blood needed, leaving extra wells for standards and controls. 100,000 PBMCs will
be required per well. Collect fresh whole blood from a consented donor. It is best to
plate the PBMCs and add the MSC-CM or lysate on the day of the separation to
ensure maximum viability. (See Note 2) We have found 5 mL of blood to safely
supply 10-15 million PBMCs, but this count varies from donor to donor.
2. Wash blood with equivalent volume of PBS, thus diluting the blood 1:2. Prepare 5
mL Ficoll for each 10 mL of diluted blood. Gently layer diluted blood on the Ficoll
column. (See Note 1)
3. Spin 30 minutes at 1500g with no brake. Collect buffy coat and wash with 5 mL
PBS.
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4. Spin 10 minutes at 1500g. Resuspend pellet in 1 mL C-10 medium and determine
cell count.
5. Dilute or concentrate to 2 million cells/ mL. Seed in 96-well plate at 50 pL per well
(100,000 cells per well). Incubate at 370C for storage if MSC-CM or lysate cannot be
added immediately.
7.1.4.5. Preparation of samples and stimulation with LPS
1. Add 50 pL of MSC-CM or lysate to each well in the blood plate and incubate at
370C for 16-18 hours.
2. Prepare LPS solution. Vortex well before dilution. Prepare 6 mL per plate of LPS
diluted in C-10. Add 50 pL to each well, thus yielding a final concentration of 10
pg/mL in the wells, and incubate at 370C or 5 hours.
3. Spin plates at 1500g for 10 minutes to settle PBMCs to the bottom of the wells.
Collect supematant in a new 96-well plate and store at -80*C. (See Note 5)
7.1.4.6. ELISA and Analysis of Results
1. Perform ELISA for human IL-10 according to manufacturer instructions. Use
spectrophotometer to read plates at wavelengths indicated by EUSA kit and import
raw data into program of choice.
2. Perform linear regression to generate standard curve and equation.
3. Convert raw absorbance data into concentration values using linear regression
equation and generate bar graph. High IL-1 0 secretion by PBMCs indicates high
potency of treatment.
7.1.5. Conclusions
MSCs are promising candidates for cell-based immunomodulatory therapy. They can be
easily isolated from bone marrow aspirates, expanded 50 population doublings in 10
weeks with minimal loss in potency, and to date have not been found to cause adverse
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immune responses in allogenic transplantation recipients [396]. Despite controversial
theories regarding the primary therapeutic mechanism of action, the uses of MSC
treatments have become diverse [392]. In our lab, we have demonstrated the effective use
of MSC-CM and MSC-Ly in treating multiple organ dysfunction syndrome. To hamess
both the secreted and intracellular metabolism of MSCs, we have also created a MSC
extracorporeal device for the treatment of organ failure [41, 42].
By quantifying the potency of MSC-CM or MSC-Ly, this method enables optimization of
dosage, growth and storage conditions, as well as treatment procedures for clinical use of
MSCs and MSC-based products. In future development of these products, the ant-
inflammatory activity that these cells possess can be measured reliably and reproducibly
with this assay, providing for better consistency and more rigorous release criteria. The
assay also provides a valuable tool in elucidating the mechanism underlying MSC
immunomodulation. The speed at which MSC transplantation conveys therapeutic activity (-
hours) is considerably faster than that of other cell transplants for regeneration purposes
(-days-weeks), an inconsistency that can only be explained if other hypotheses for the
mechanism of action other than engraftment and differentiation are considered. The time
scale of these results could plausibly be explained by the occurrence of MSC lysis and the
release of what would be paracrine factors during transplantation. This potency assay can
account for and facilitate decomposing the "lysate effect".
7.1.6. Notes
1. It is recommended that the bone marrow or blood be diluted 1:1 with PBS, as the
larger volume provides a greater margin of error during the collection of the buffy
coat.
2. We found that blood stored for prolonged periods before use tends to be activated
during storage and can thereby confound the results of the assay. Freshly obtained
PBMCs are preferred.
3. Phenotype and Multipotency Analysis
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While the identities of relevant cell surface markers of human MSCs remain
controversial, Table 1 offers a certain immunophenotype of MSCs. It is possible to
label for certain cell surface markers and conduct flow cytometry for isolation.
Table Al - Immunophenotype of Human MSCs
Positive Negative Inducible
CD13, CD29, CD44, CD49a, b, c, e, f, CD51, CD54, CD3, CD4, CD6, CD9, CD10, CD11 a, HLA-DR
CD58, CD71, CD73, CD90, CD1 02, CD1 05, CD14, CD15, CD18, CD21, CD25,
CD1 06, CDw1 19, CD1 20a, CD1 20b, CD1 23, CD31, CD34, CD36, CD38, CD45,
CD1 24, CD1 26, CD1 27, CD140a, CD1 66, P75, CD49d, CD50, CD62E, L, S, CD80,
TGF-blR, TGF-bllR, HLA-A, B, C, SSEA-3, SSEA-4, CD86, CD95, CD117, CD133, SSEA-1,
D7, PD-L1 ABO
Note: CD, cluster of differentiation; TGF, transforming growth factor; HLA, human leukocyte antigen; SSEA,
stage-specific embryonic antigen; ABO refers to blood group antigens
MSCs have been shown to be capable of differentiating into bone, cartilage,
adipose cells, and myoblasts in vivo [392]. Lee et al. developed differentiation media
in which, under the right conditions, MSCs can be observed to differentiate into
these tissues in vitro [397]. Table 2 includes specialized media used to encourage
differentiation of MSCs. MSC differentiation kits are also commercially available
from vendors.
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Table A2 - Differentiation Media for MSCs
Differentiation Medium Composition
Osteogenic IMDM with 0.1 pM dexamethasone (Sigma-Aldrich, St Louis, MO), 0.2 mM
ascorbic acid (AsA; Sigma-Aldrich), 10 mM -glycerol phosphate (Sigma-
Aldrich).
Chondrogenic high-glucose DMEM (Bio-fluid, Rockville, MD) with 0.1 M dexamethasone,
50 g/mL AsA, 100 g/mL sodium pyruvate(Sigma-Aldrich), 40 g/mL proline
(Sigma-Aldrich), 10 ng/mL TGF- 1, and 50 mg/mL ITS premix (Becton
Dickinson; 6.25 g/mL insulin, 6.25 g/mL transferrin, 6.25 ng/mL selenius
acid, 1.25 mg/mL bovine serum albumin (BSA), and 5.35 mg/mL linoleic
acid).
Adipogenic IMDM with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), 1 M
hydrocortisone (Sigma-Aldrich), 0.1 mM indomethacin(Sigma-Aldrch), and
10% rabbit serum (Sigma-Aldrich).
It is also possible to perform multipotency tests in vivo through subcutaneous
transplantation of MSCs. While it is beyond the scope of this paper to discuss in
vivo assays, the reader may find it worthwhile to refer to the work of Bianco and
colleagues conceming the formation of ectopic bone marrow using subcutaneous
transplants of MSCs [398].
4. This volume is typically 15 mL for Coming T-1 75 Flasks. For other containers a
similar volume per cell ratio should be achieved, although small variations are
negligible as the final definition of 1X and 1OX medium are based on cell count and
not initial volume.
5. Despite centrifugation, the supematant may still be contaminated with PBMCs
during the collection process. Freezing before the ELISA is recommended to lyse all
remaining cells.
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